CA2598680A1 - Particles - Google Patents

Particles Download PDF

Info

Publication number
CA2598680A1
CA2598680A1 CA002598680A CA2598680A CA2598680A1 CA 2598680 A1 CA2598680 A1 CA 2598680A1 CA 002598680 A CA002598680 A CA 002598680A CA 2598680 A CA2598680 A CA 2598680A CA 2598680 A1 CA2598680 A1 CA 2598680A1
Authority
CA
Canada
Prior art keywords
particle
particles
microns
atmospheres
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002598680A
Other languages
French (fr)
Inventor
Steven M. Anderson
Janel Lanphere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Scientific Ltd Barbados
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2598680A1 publication Critical patent/CA2598680A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984Microcapsule with fluid core [includes liposome]

Abstract

A particle with a diameter of at most about 3,000 microns has an internal pressure of at least about 1.1 atmospheres at a temperature of less than about 25~C.

Description

Particles TECHNICAL FIELD
The invention relates to particles, as well as related compositions and methods.
BACKGROUND
Energy, such as RF energy, can be employed (e.g., in a tissue ablation procedure) to degrade unhealtlly or unwanted tissue, such as warts, moles, cysts, scar tissue, and/or tumors. In some cases, for example, an RF electrode can be delivered into the unhealthy or unwanted tissue via a catheter. Once positioned within the tumor, RF-emitting tines can be deployed and activated. Upon activation, the tines can emit RF energy to degrade the tissue by, for example, heating the tissue.

SUMMARY
In one aspect, the invention features a particle with a diameter of at most about 3,000 microns and an internal pressure of at least about 1.1 atmospheres at a teinperature of less than about 25 C (e.g., at a temperature of about 20 C).
In aiiother aspect, the invention features a particle including a gas generator and having a diameter of at most about 3,000 microns. When the gas generator is heated to a temperature of at least about 35 C, the internal pressure of the particle increases to at least about 1.5 atmospheres.
In an additional aspect, the invention features a composition including a carrier fluid and particles disposed within the carrier fluid. The particles have an arithmetic mean diameter of at most about 3,000 microns. The enviromnent surrounding the composition has a pressure of at least about 1.1 atmospheres (e.g., from about 1.1 atmospheres to about 1.5 atmospheres).
In a further aspect, the invention features a composition including a carrier fluid and particles disposed within the carrier fluid: The particles have an arithmetic mean diameter of at most about 3,000 microns. The temperature of the environment surrounding the coinposition is at most about 20 C (e.g., at most about 10 C).
In another aspect, the invention features a capsule including at least one particle having a diameter of at most about 3,000 microns and an internal pressure of at least about 1.1 atmospheres at a temperature of less than about 25 C (e.g., at a temperature of about 20 C). The capsule has a maximum dimension of from about 3,000 microns to about 5,000 microns.
In an additional aspect, the invention features a method that includes exposing a particle with an internal pressure of at least about 1.1 atmospheres at a temperature of less than about 25 C (e.g., at a temperature of about 20 C) to a temperature of at least about 35 C. The particle has a diameter of at mo t st about 3,000 inicrons.
In a further aspect, the invention features a method including increasing the internal pressure of a particle by at least about five percent (e.g., from about five percent to about 50 percent). The particle has a diameter of at most about 3,000 microns.
In another aspect, the invention features a method that includes exposing a particle to a first teinperature of at most abbut 20 C (e.g., from about 0 C
to about 20 C, from about 4 C to about 20 C), and exposing the particle to a second temperature of at least about 35 C (e.g., at least about 37 C, at least about 90 C) to burst the particle. The particle has a diaineter of at most about 3;000 microns.
In an additional aspect, the invention features a metllod that includes delivering a particle with a diameter of at most about 3,000 microns, and an internal pressure of about 1.5 atmospheres at a temperature of abouf'35 C, into the tissue of a subject.
In a further aspect, the invention features a metllod of malcing a particle that has an intenial pressure of at least about 1.1 atmospheres at a temperature of less than about C (e.g., at a temperature of about 20 C), and a diameter of at most about 3,000 inicrons. The method includes fonning a particle precursor in an enviromnent having a pressure of at least about 1.1 atmospheres, and coating the particle precursor to form the particle.
25 In another aspect, the invention features a method of malcing a particle having an internal pressure of at least about 1.1 atmospheres at a temperature of less than about 25 C and a diameter of at most about 3,000 microns. The method includes fonning the particle at a temperature of at most about 20 C.
Embodiments may also include one or'more of the following.
In certain embodiments, the particle can include (e.g., encapsulate) one or more gases, such as carbon dioxide, nitrogen, oxygen, or water vapor.
In certain embodiments, the particle can have an internal pressure of at least about 1.1 atmospheres at a temperature of about 20 C, at least about 1.2 atmospheres at a temperature of about 25 C, at least about 1.3 atmospheres at a temperature of about 30 C, and/or at least about 1.5 atmospheres at a temperature of at least about 35 C.
In some embodiments, the particle can have an internal pressure of at least about 1.5 atmospheres at a temperature of at least about 90 C (e.g., froin about 90 C to about 95 C).
When the particle is heated to a temperature of at least about 25 C (e.g., at least about 35 C, at least about 90 C), the internal pressure of the particle can increase by at least about five percent (e.g., at least about 10 percent, at least about 20 percent, at least about 30 percent, at least about 40 percent).
In some embodiments, the particle can burst at a temperature of at least about 35 C (e.g., at least about 90 C, from about 90 C to about 95 C), and/or at an internal pressure of at least about 1.2 atmospheres (e.g., at least about 1.3 atmospheres, at least about 1.4 atmospheres, at least about 1.5 atmospheres).
The particle can include a gas generator, and when the gas generator is heated to a temperature of at least about 25 C (e.g., at least about 30 C, at least about 35 C, at least about 90 C, at least about 100 C), the intemal pressure of the particle can increase. For exainple, when the gas generator is heated to a temperature of from about 90 C
to about 95 C, the internal pressure of the particle can increase. In certain embodiments, the internal pressure of the particle can increase to at least about 1.2 atmospheres (e.g., at least about 1.3 atmospheres, at least about 1.4 atmospheres, at least about 1.5 atmospheres), and/or by at least about five percent (e.g., at least about 10 percent, at least about 20 percent, at least about 30 percent, at least about 40 percent). In some embodiments, the internal pressure of the pai-ticle can increase by from about five percent to about 50 percent.
The gas generator can include, for exainple, dry ice, ice, water, and/or saline. The gas generator can be disposed in an interior region of the particle, and/or can be disposed within one or more pores of the particle. When exposed to a temperature of at least about 25 C (e.g., at least about 30 C, at least about 35 C), the gas generator can generate gas (e.g., carbon dioxide, water vapor).
The particle can include one or more thermally conductive materials, such as a metal (e.g., iron, aluminum, cobalt, copper, silver, molybdenum, zinc, gold, iridium) or a metal alloy (e.g., steel). In some einbodiments, the particle can include a non-inetal thermally conductive material, such as silicon or carbon. In certain embodiments, the particle can include one or more electrically conductive materials, such as a metal (e.g., silver, copper, gold, aluminum, iridium, zinc, iron, nickel, molybdenum, cobalt) or a metal alloy (e.g., steel). In certain embodiments, the particle can include one or more materials that are both thermally conductive and electrically conductive, such as silver, copper, gold, aluminum, iridiuin, molybdenuin, zinc, or steel.
In some einbodiments, the particle can include a polyiner, such as a polyvinyl alcohol, a polyacrylic acid, a polymethacrylic acid, a poly vinyl sulfonate, a carboxyinethyl cellulose, a hydroxyethyl celluloses, a substituted cellulose, a polyacrylamide, a polyethylene glycol, a polyamide, a polyurea, a polyurethane, a polyester, a polyether, a polystyrene, a polysaccharide, a polylactic acid, a polyetllylene, a polymetllylmethacrylate, a polycaprolactone, a polyglycolic acid, a poly(lactic-co-glycolic) acid (e.g., a poly(d-lactic-co-glycolic) acid), or a copolymer or mixture thereof.
In some embodiments, the particle can include a gelling precursor, such as alginate, an alginate salt, a xanthan gum, natural gum, agar, agarose, chitosan, carrageenan, fucoidan, furcellaran, laminaran, hypnea, eucheuma, gum arabic, guin ghatti, gum karaya, gum tragacanth, hyalauronic acid, locust beain gum, arabinogalactan, pectin, or amylopectin. For example, the particle can include sodium alginate.
The particle can include a ferromagnetic material. In some embodiments, at least some of the ferromagnetic material can be disposed within an interior region of the particle. The ferromagnetic material can be a transition metal (e.g., nickel, cobalt, iron), a metal alloy (e.g., Mu-metal), or a metal oxide (e.g., magnetite). In certain embodiments, the ferromagnetic material can be a soft ferrite, a rare-earth magnet alloy, or an amorphous and non-earth alloy. The ferromagnetic material can be, for exarnple, in the shape of at least one article that is a particle, fiber, flalce, or powder, and/or that has a diameter of from about two microns to about 20 microns.
In some embodiments in which the particle includes a ferromagnetic material, exposing the particle to a temperature of at least about 35 C can cause at least some of the ferromagnetic material to be released from the particle. At least some of the ferromagnetic material can be released into the tissue of a subject.
The particle can be porous. The particle can have a porous region. The pore density of an interior region of the particle can be greater than the pore density of an exterior region of the particle.
The particle can include a coating. The coating can have a thickness of at most 0.02 inch (e.g., from 0.001 inch to 0.02 inch). In certain einbodiments, the coating can have a thiclcness of at most 0.004 inch (e.g., from 0.00004 inch to 0.004 inch).
The particle can be substantially spherical.
The capsule can include a plurality of particles, and/or can have an internal pressure of at least about 1.1 atmospheres.
Exposing the particle to a temperature'of least about 35 C (e.g., at least about 37 C, at least about 90 C) can cause the internal pressure of the particle to increase to at least about 1.5 atmospheres, and/or can cause the particle to burst. The particle can be exposed to a temperature of at least about 35 C (e.g., at least about 37 C, at least about 90 C) by delivering the particle into the tissue of a subject (e.g., tissue that includes a tumor). Delivering a particle into the tissue of a subject can include exposing the particle to an external pressure of at least about one atmosphere. In some einbodiments, exposing the particle to a temperature of at least about 35 C (e.g., at least about 37 C, at least about 90 C) can include heating the particle. In certain embodiments, an RF
electrode can be used to heat the particle. In some embodiments, the method can further include ablating at least a portion of the tissue of the subject. In certain embodiments, increasing the internal pressure of the particle by at least about five percent can cause the particle to burst.
The method can furtlier include contacting the particle with an agent (e.g., an alcohol, hydrochloric acid, sodiuin hydroxide, sodium citrate, sodium hexa-metaphosphate) that can dissolve or erode at least a portion of the particle.
The particle can include a therapeutic agent. Exposing the particle to a temperature of at least about 35 C (e.g., at least about 37 C, at least about 90 C) can include releasing the therapeutic agent fiom the particle.
Einbodiinents can include one or more of the following advantages.
In some embodiments, the particle, can enhance tissue heating and/or ablation procedures. For example, in embodiments in which the particle includes a ferromagnetic material, the ferromagnetic material can be released from the particle when the particle bursts at a target site (e.g., within the tissue of a subject). In certain embodiments, the ferromagnetic material can be delivered to the target site relatively quiclcly, and/or can be distributed relatively uniformly throughout and/or on top of the target site.
When exposed to RF radiation, the ferromagnetic material can become heated and, in turn, can heat (e.g., ablate) the target site (e.g., the tissue). A relatively uniform distribution of the ferromagnetic material throughout and/or on top of the target site can provide for relatively even ablation of the target site and, correspondingly, for a relatively uniform and consistent burn.
In certain embodiments, the particle can be used to deliver one or more therapeutic agents (e.g., drugs) to a target site relatively efficiently and effectively. For exainple, once delivered to a target site, the particle can burst, and can thereby release therapeutic agent. In some embodiments, the particle can be used to deliver a therapeutic agent directly to the target site, such that the therapeutic agent can have an immediate effect on the target site. In certain embodiments, the particle can provide for the relatively wide and/or uniform distribution of therapeutic agent at a target site.
In some embodiments, the particle can be used both to enhance tissue heating and/or ablation procedures, and to provide one or more therapeutic agents to a target site.
For example, a particle can include both a ferromagnetic material and a therapeutic agent.
When the particle bursts at a target site, the particle can release the ferromagnetic material and the therapeutic agent to the target site, such that the ferromagnetic material can be used in a tissue heating/ablation procedure, and the tllerapeutic agent can be used to treat the target site.
Features and advantages are in the description, drawings, and claims.
DESCRIPTION OF DRAWINGS
FIG 1 A is a cross-sectional view of an embodiment of a particle.
FIG. 1B is a cross-sectional view of the particle of FIG 1A, as the particle is bursting.
FIG. 2A is a cross-sectional view of a cancerous liver of a subject.
FIG 2B illustrates administration of the particles of FIG 1 A into the liver of FIG 2A.
FIG 2C is a cross-sectional view of the liver of FIGS. 2A and 2B, after the particles have been administered into the liver.
FIG 2D is a cross-sectional view of the liver of FIGS. 2A, 2B, and 2C, after the particles have burst.
FIG 2E illustrates an RF electrode with tines deployed within the cancerous tissue region of the liver of FIGS. 2A, 2B, 2C, and 2D.
FIG 3 is a cross-sectional view of an einbodiinent of a particle.
FIG 4A is a cross-sectional view of an embodiment of a particle.
FIG 4B is a cross-sectional view of an embodiment of a particle.
FIG 5A is a schematic of the manufacture of particles.
FIG 5B is an enlarged schematic of region 5B in FIG 5A.
FIG 6A is a cross-sectional view of an embodiment of an apparatus for producing particles.
FIG 6B is an illustration of the production of particles by the apparatus of FIG
6A.
FIG 7 is a side view of an einbodiment of a capsule of particles.
FIG 8A is a cross-sectional view of a liver of a subject.
FIG 8B illustrates delivery of a cannula into the liver of FIG 8A.
FIG 8C illustrates administration of particles into the liver of FIG 8A.
FIG 8D is a cross-sectional view of the liver of FIG 8A, after the particles have been administered into the liver.
FIG 8E illustrates delivery of an RF electrode into the liver of FIG 8A.
FIG 8F illustrates an RF electrode with tines deployed within the cancerous tissue region of the liver of FIG. 8A.
FIG 9 is a cross-sectional view of an embodiment of a particle.
FIG 1 OA is a cross-sectional view of an embodiment of a particle.
FIG 1 OB is a cross-sectional view of an einbodiment of a particle.
DETAILED DESCRIPTION
FIG 1A shows a particle 10-A at a temperature of less than about 25 C.
Particle 10-A has a coating 12 that encloses an interior region 14 formed of a matrix 18 and ferromagnetic particles 16. Poclcets 20 of carbon dioxide gas are dispersed throughout matrix 18. At a temperature of less than about 25 C, particle 10-Ahas an intern.al presstire of at least about 1.1 atmospheres.
FIG 1B shows a burst particle 10-B, which is the result of the exposure of particle 10-A to a teinperature of at least abottt 35 C. The increase in temperature results in an increase in the pressure of the carbon dioxide gas within pockets 20, and thus in the internal pressure of particle 10-A. This increase in internal pressure eventually causes particle 10-A to burst, forming burst particle 10-B. When particle 10-A
bursts, it releases ferromagnetic particles 16.
In general, the internal pressure of particle 10-A at a given temperature can be selected so that when particle 10-A is heated to a certain higher temperature, particle 10-A will burst. Iii some embodiments, at a temperature of less than about 25 C, particle 10-A can have an internal pressure of at least about 1.1 atmospheres (e.g., at least about 1.2 atmospheres, at least about 1.3 atmospheres, at least about 1.4 atmospheres, at least about 1.5 atmospheres, at least about two atmospheres, at least about three atmospheres, at least about four atmospheres), and/or at most about five atmospheres (e.g., at most about four atmospheres, at most about three atmospheres, at most about two atmospheres, at most about 1.5 atmospheres, at most about 1.4 atmospheres, at most about 1.3 atmospheres, at most about 1.2 atmospheres). In certain embodiments, at a temperature of less than about C (e.g., at a temperature of from abotit 0 C to about 20 C, at a temperattire of from about 4 C to about 20 C, at a teinperature of about 20 C), particle 10-A can have an 25 internal pressure of from about 1.1 atmospheres to about 1.5 atmospheres.
Generally, as the temperature of the enviromnent surrounding particle 10-A
(and, therefore, the temperature of particle 10-A itself) increases, the internal pressure of particle 10-A can also increase. In certain einbodunents, the increase in the temperattire of particle 10-A (e.g., to at least abottt 25 C, at least about 35 C, or at least about 90 C) can cause the internal presstire of particle 10-A to increase by at least abotit five percent (e.g., at least about 10 percent, at least about 20 percent, at least about 30 percent, at least about 40 percent). For example, the internal pressure of particle 10-A can increase by from about five percent to about 50 percent as the temperature of particle 10-A increases (e.g., to at least about 25 C, at least about 35 C, or at least about 90 C).
In some embodiments, the increase in the temperature of particle 10-A can cause the internal pressure of particle 10-A to increase to at least about 1.2 atmospheres (e.g., at least about 1.3 atinospheres, at least about 1.4 atmospheres, at least about 1.5 atinospheres).
In some embodiments, particle 10-A can burst when the internal pressure of particle 10-A is at least about 1.1 atmospheres (e.g., at least about 1.2 atmospheres, at least about 1.3 atmospheres, at least about 1.4 atmospheres, at least about 1.5 atmospheres, at least about two atmospheres, at least about three atmospheres, at least about four atmospheres), and/or at most about five atinospheres (e.g., at most about four atmospheres, at most about three atmospheres, at most about two atmospheres, at most about 1.5 atmospheres, at most about 1.4 atmospheres, at most about 1.3 atmospheres, at most about 1.2 atinospheres). In certain embodiments, particle 10-A can be designed to burst once particle 10-A has reached a predetermined internal pressure.
In some embodiments, particle 10-A can be designed to burst once particle 10-A
has reached a predetennined temperature. In certain embodiments, particle 10-A
can burst at a teinperature of at least about 20 C (e.g., at least about 25 C, at least about 30 C, at least about 35 C, at least about 40 C, at least about 50 C, at least about 60 C, at least about 70 C, at least about 80 C, at least about 90 C, at least about 100 C, at least about 125 C, at least about 150 C, at least about 175 C), and/or at most about (e.g., at most about 175 C, at most about 150 C, at most about 125 C, at most about 100 C, at most about 90 C, at most about 80 C, at most about 70 C, at most about 60 C, at most about 50 C, at most about 40 C, at most about 35 C, at most about 30 C, at most about 25 C). For example, particle 10-A can burst at about 37 C.
The teinperature at which particle 10-A bursts can be selected, for example, based on the application(s) for which particle 10-A is being used. For example, if particle 10-A
is being used for an RF ablation procedure (such as the procedure described below with reference to FIGS. 2A-2E), it may be desirable for particle 10-A to remain intact until the target site has been sufficiently heated. In some einbodiments in which particle 10-A is to be used in an ablation procedure, particle 10-A may be designed to burst at a temperature of at least about 90 C (e.g., from about 90 C to about 95 C).
Typically, the tliickness of coating 12 of particle 10-A can be selected to accommodate an increase in the internal pressure of particle 10-A to a predetermined level, at which point particle 10-A may burst. In some einbodiments, coating 12 can have a thickness of at most 0.02 inch (e.g., at most 0.01 inch, at most 0.005 inch, at most 0.004 inch), and/or at least 0.00004 inch (e.g., at least 0.004 inch, at least 0.005 inch, at least 0.01 inch). For example, coating 12 may have a thiclcness of from 0.00004 inch to 0.02 inch (e.g., from 0.001 inch to 0.02 inch).
Coating 12 and matrix 18 of particle 10-A can be formed of the same materials or different materials. In some embodiments, coating 12 and/or matrix 18 can be formed of at least one polymer and/or at least one non-polymer. In certain einbodiments, coating 12 and/or matrix 18 can be formed of at least gelling precursor. In general, coating 12 and/or matrix 18 can be fonned of one or more materials that are biocompatible, bioerodible, and/or bioabsorbable.
Examples of polymers include polyvinyl alcohols, polyacrylic acids, polymethacrylic acids, poly vinyl sulfonates, carboxymethyl celluloses, hydroxyethyl celluloses, substituted celluloses, polyacrylamides, polyethylene glycols, polyamides (e.g., nylon), polyureas, polyurethanes, polyesters, polyetllers, polystyrenes, polysaccharides (e.g., alginate, agarose), polylactic acids, polyethylenes, polymethylmethacrylates, polyethylacrylate, polycaprolactones, polyglycolic acids, poly(lactic-co-glycolic) acids (e.g., poly(d-lactic-co-glycolic) acids), and copolymers or mixtures thereof. In certain embodiments, the polymer can be a highly water insoluble, high molecular weight polymer. An example of such a polymer is a high molecular weight polyvinyl alcohol (PVA) that has been acetalized. The polymer can be substantially pure intrachain 1,3-acetalized PVA and substantially free of animal derived residue such as collagen.
Examples of gelling precursors include alginates, alginate salts (e.g. sodium alginate), xanthan gums, natural gum, agar, agarose, chitosan, carrageenan, fucoidan, fiircellaran, laminaran, hypnea, eucheuma, gum arabic, gum ghatti, gum karaya, gum tragacantli, hyalauronic acid, locust beam gum, arabinogalactan, pectin, amylopectin, other water soluble polysaccharides and other ionically cross-linlcable polymers. A
particular gelling precursor is sodium alginate. A preferred sodium alginate is high guluronic acid, stem-derived alginate (e.g., about 50 percent or more, about 60 percent or more guluronic acid) with a low viscosity (e.g., from about 20 centipoise to about 80 centipoise at 20 C), which produces a high tensile, robust gel.
Examples of bioerodible and/or bioabsorbable materials include polysaccharides (e.g., alginate); polysaccharide derivatives; inorganic, ionic salts; water soluble polylners (e.g., polyvinyl alcohol, such as polyvinyl alcohol that has not been cross-linlced);
biodegradable poly DL-lactide-poly ethylene glycol (PELA); hydrogels (e.g., polyacrylic acid, haluronic acid, gelatin, carboxymethyl cellulose); polyethylene glycol (PEG);
chitosan; polyesters (e.g., polycaprolactones); poly(lactic-co-glycolic) acid (e.g., a poly(d-lactic-co-glycolic) acid); and combinations thereof. In some einbodiments, a coating can include sodium alginate.
In certain embodiments in which a coating is fonned of a bioerodible and/or bioabsorbable material, the coating can begin to erode once it has been delivered into the body. For example, the coating may be designed to erode upon contact with blood. The erosion of the coating can result in a reduction in the thickness of the coating, which can accelerate the bursting of the particle once the internal pressure of the particle has reached a predetermined level. In some einbodiinents in which a coating is fonned of one or more bioerodible and/or bioabsorbable materials, the coating can be relatively thick prior to delivery to a target site. This thickness can, for example, provide enhanced durability to the particle during storage and/or delivery.
In certain embodiments, a particle can include inultiple (e.g., two, three, four, five) coatings fonned of one or more of the materials described above.
Ferromagnetic particles 16 can include one type ferromagnetic material, or multiple types of ferromagnetic materials. In some embodiments, some ferromagnetic particles 16 are formed of one type of feiTomagnetic material, while others ferromagnetic particles 16 are fonned of a different type of ferromagnetic material. As used herein, a ferromagnetic material refers to a material that has a magnetic susceptibility of at least about 0.075 or more (e.g., at least about 0.1 or more; at least about 0.2 or more; at least about 0.3 or more; at least about 0.4 or more; at least about 0.5 or more; at least about one or more; at least about 10 or more; at least about 100 or more; at least about 1,000 or more; at least about 10,000 or more) when measured at 25 C. A ferromagnetic material can be, for example, a metal (e.g., a transition metal such as niclcel, cobalt, or iron), a metal alloy (e.g., a nickel-iron alloy such as Mu-metal), a metal oxide (e.g., an iron oxide such as magnetite), a ceramic nanomaterial, a soft ferrite (e.g., nicleel-zinc-iron), a magnet alloy (e.g., a rare earth magnet alloy such as a neodymium-iron-boron alloy or a samarium-cobalt alloy), an amorphous alloy (e.g., iron-silicon-boron), a non-earth alloy, or a silicon alloy (e.g., an iron-zirconium-copper-boron-silicon alloy, an iron-zirconiuin-copper-boron-silicon alloy). Magnetite is commercially available from FerroTec Corporation (Nashua, NH), under the tradename EMG 1111 Ferrofluid. Iron-copper-niobium-boron-silicon alloys are commercially available from Hitachi Metals of America under the tradename FinemetTM. Iron-zirconium-copper-boron-silicon alloys are commercially available from MAGNETEC GmbH under the tradenaine Nanoperrri .
Typically, the ferromagnetic material can be a biocompatible material. In some einbodiments, the ferromagnetic material is a bioerodible material, such that the material can eventually brealc down in the body and either be dispersed throughout the body or excreted from the body. In certain embodiments, the ferromagnetic material may not be biocoinpatible. In such einbodiments, the ferromagnetic material may be encapsulated in a biocompatible material, such as polyvinyl alcohol or sodiuin alginate.
Typically, the velocity at which ferromagnetic particles 16 exit particle 10-A
when particle 10-A bursts can be selected to distribute ferromagnetic particles 16 sufficiently across the target site.
In general, particle 10-A can have a diameter of at most about 3,000 microns (e.g., from about two microns to about 3,000 microns, from about 10 inicrons to about 3,000 microns, from about 40 microns to about 2,000 microns; from about 100 microns to about 700 microns; from about 500 microns to about 700 microns; from about microns to about 500 microns; from about 100 microns to about 300 microns;
from about 300 microns to abotit 500 microns; from about 500 microns to about 1,200 microns; from about 500 microns to about 700 microns; from about 7001nicrons to about 900 microns;
from about 900 microns to about 1,200 microns). In some embodiments, particle can have a diameter of at most about 3,000 microns (e.g., at most about 2,500 microns; at most about 2,000 microns; at most about 1,500 microns; at most about 1,200 microns; at most about 1,000 microns; at most about 900 microns; at most about 700 microns; at most about 500 microns; at most about 400 microns; at most about 300 microns;
at most about 100 microns), and/or at least about two microns (e.g., at least about 10 microns, at least about 100 microns; at least about 300 microns; at least about 400 microns; at least about 500 microns; at least about 700 microns; at least about 900 microns; at least about 1,000 microns; at least about 1,200 microns; at least about 1,500 microns; at least about 2,000 microns; at least about 2,500 microns).
In certain embodiments, particle 10-A can be substantially spherical. In some embodiments, particle 10-A can have a sphericity of about 0.8 or more (e.g., about 0.85 or more, about 0.9 or more, about 0.95 or more, about 0.97 or more). Particle 10-A can be, for exainple, manually compressed, essentially flattened, while wet to about 50 percent or less of its original diameter and then, upon exposure to fluid, regain a sphericity of about 0.8 or more (e.g., about 0.85 or more, about 0.9 or more, about 0.95 or more, about 0.97 or more). The sphericity of a particle can be determined using a Beclm-ian Coulter RapidVUE Image Analyzer version 2.06 (Beclanan Coulter, Miami, FL). Briefly, the RapidVUE talces an image of continuous-tone (gray-scale) form and converts it to a digital form through the process of sampling and quantization. The system software identifies and measures particles in an image in the form of a fiber, rod or sphere. The sphericity of a particle, which is coinputed as Da/Dp (where Da =
4(4A/7r); Dp = Phu ; A = pixel area; P= pixel perimeter), is a value from zero to one, with one representing a perfect circle.
Typically, wlien used, particles 10-A can be disposed within a carrier fluid to form a composition (e.g., a suspension) which can then be delivered to a target site. The carrier fluid can be, for example, a pharmaceutically acceptable carrier, such as saline, contrast agent, therapeutic agent, or a coinbination of these carriers. In some embodiments, the carrier fluid can include deionized water, water for injection, liquid polymer, gel polymer, gas, or a combination of these carriers.
Compositions that include particles such as particles 10-A can be delivered to various sites in the body, including, for exainple, sites having cancerous lesions, such as the breast, prostate, lung, thyroid, or ovaries. The coinpositions can be used in the treatment of, for example, fibroids, tumors, internal bleeding, arteriovenous malformations (AVMs), and/or hypervascular tumors. Fibroids can include uterine fibroids which grow within the uterine wall (intramural type), on the outside of the uterus (subserosal type), inside the uterine cavity (submucosal type), between the layers of broad ligament supporting the uterus (interligamentous type), attached to anotlier organ (parasitic type), or on a mushroom-like stalk (pedunculated type). Internal bleeding includes gastrointestinal, urinary, renal and varicose bleeding. AVMs are for example, abnormal collections of blood vessels, e.g. in the brain, which shunt blood from a high pressure artery to a low pressure vein, resulting in hypoxia and malnutrition of those regions from which the blood is diverted. In some embodiments, a composition containing the particles can be used to prophylactically treat a condition.
The magnitude of a dose of a coinposition can vary based on the nature, location and severity of the condition to be treated, as well as the route of administration. A
physician treating the condition, disease or disorder can determine an effective amount of composition. An effective amount of composition refers to the amount sufficient to result in amelioration of symptoms or a prolongation of stirvival of the subject. The compositions can be administered as phannaceutically acceptable compositions to a subject in any therapeutically acceptable dosage, including those administered to a subject intravenously, subcutaneously, percutaneously, intratrachealy, intramuscularly, intramucosaly, intracutaneously, intra-articularly, intra-arterially, orally or parenterally.
A composition can include a mixture of particles (e.g., particles that have different internal pressures, particles that include different types of ferromagnetic materials), or can include particles that are all of the same type. In some embodiinents, a composition can be prepared with a calibrated concentration of particles for ease of delivery by a physician. A physician can select a composition of a particular concentration based on, for example, the type of procedure to be perfonned. In certain einbodiments, a pliysician can use a composition with a relatively high concentration of particles during one part of a procedure, and a composition with a relatively low concentration of particles during another part of a procedure.
Suspensions of particles in saline solution can be prepared to remain stable (e.g., to remain suspended in soltition and not settle and/or float) over a desired period of time.

A suspension of particles can be stable, for example, for from about one minute to about 20 minutes (e.g. from about one minute to about 10 minutes, from about two minutes to about seven minutes, from about three minutes to about six minutes).
In some embodiments, particles can be suspended in a physiological solution by matching the density of the solution to the density of the particles. In certain embodiments, the particles and/or the physiological solution can have a density of from about one gram per cubic centimeter to about 1.5 grams per cubic centimeter (e.g., from about 1.2 grams per cubic centimeter to about 1.4 grams per cubic centimeter, from about 1.2 grams per cubic centimeter to about 1.3 grams per cttbic centimeter).
In some embodiments, the carrier fluid of a composition can include a surfactant.
The surfactant can help the particles to mix evenly in the carrier fluid and/or can decrease the likelihood of the occlusion of a delivery device (e.g., a catlieter) by the particles. In certain embodiments, the surfactant can enhance delivery of the composition (e.g., by enhancing the wetting properties of the particles and facilitating the passage of the particles through a delivery device). In some einbodiinents, the surfactant can decrease the occurrence of air entrapment by the particles in a composition (e.g., by porous 80 (available particles in a composition). Examples of liquid surfactants include Tween from Sigma-Aldrich) and Cremophor EL (available from Sigma-Aldrich). An example of a powder surfactant is Pluronic F127 NF (available from BASF). In certain embodiments, a coinposition can include from about 0.05 percent by weight to about one percent by weight (e.g., about 0.1 percent by weight, about 0.5 percent by weight) of a surfactant. A surfactant can be added to the carrier fluid prior to mixing with the particles and/or can be added to the particles prior to mixing with the carrier fluid.
In some embodiments, ainong the particles delivered to a subject in a composition, the majority (e.g., at least about 50 percent, at least about 60 percent, at least about 70 percent, at least about 80 percent, at least about 90 percent) of the particles can have a diameter of at most about 3,000 inicrons (e.g., at most about 2,500 microns; at most about 2,000 microns; at most abotit 1,500 microns; at most about 1,200 microns; at most about 900 microns; at most about 700 microns; at most about 500 microns;
at most about 400 microns; at most abotit 300 microns; at most about 100 microns), and/or at least about 10 microns (e.g., at least about 100 microns; at least about 300 microns; at least about 400 microns; at least about 500 microns; at least about 700 microns; at least about 900 microns; at least about 1,200 microns; at least about 1,500 microns;
at least about 2,000 microns; at least about 2,500 microns).
In certain embodiments, the particles delivered to a subject in a coinposition have an arithmetic mean diameter of at most about 3,000 microns (e.g., at most about 2,500 microns; at most about 2,000 microns; at most about 1,500 microns; at most about 1,200 microns; at most about 900 microns; at most about 700 microns; at most about microns; at most about 400 microns; at most about 300 microns; at most about microns), and/or at least about 10 microns (e.g., at least about 100 microns;
at least about 300 microns; at least about 400 microns; at least about 500 microns; at least about 700 microns; at least about 900 microns; at least about 1,200 microns; at least about 1,500 microns; at least about 2,000 microns; at least about 2,500 microns).
Exeinplary ranges for the arithmetic mean diameter of particles delivered to a subject include from about 100 microns to about 500 microns; from about 100 microns to about 300 microns;
from about 300 microns to about 500 microns; from about 500 microns to about 700 microns;
and from about 900 microns to about 1,200 microns. In general, the particles delivered to a subject in a composition can have an arithmetic mean diameter in approximately the middle of the range of the diameters of the individual particles, and a variance of at most about 20 percent (e.g., at most about 15 percent, at most about 10 percent).
In some embodiments, the arithmetic mean diameter of the particles delivered to a subject in a composition can vary depending upon the particular condition to be treated.
As an example, in embodiments in which the particles in a composition are used to treat a liver tumor, the particles delivered to the subject can have an arithmetic mean diameter of at most about 500 microns (e.g., from about 100 microns to about 300 microns;
from about 300 microns to about 500 microns). As another example, in einbodiments in which the particles in a coinposition are used to treat a uterine fibroid, the particles delivered to the subject in a composition can have an arithinetic mean diameter of at most about 1,200 microns (e.g., from about 500 microns to about 700 microns; from about 700 microns to about 900 microns; from about 900 microns to about 1,200 microns).
The arithmetic mean diaineter of a group of particles can be detennined using a Beclanan Coulter RapidVUE Iinage Aiialyzer version 2.06 (Beclanan Coulter, Miami, FL), described above. The arithmetic mean diameter of a group of particles (e.g., in a composition) can be determined by dividing the sum of the diameters of all of the particles in the group by the number of particles in the group.
A particle such as particle 10-A can be used, for example, to enhance tissue heating and/or an ablation procedure. For example, FIGS. 2A-2E illustrate the use of multiple particles 10-A in an ablation procedure that involves the exposure of unhealthy tissue to RF energy to damage or destroy the unhealthy tissue.
FIG 2A shows a portion 100 of a subject including a liver 110 and skin 120.
Liver 110 includes healthy tissue 130 and unhealthy tissue 140 (e.g., cancerous tissue, such as a cancerous tumor). FIG 2B illustrates the delivery of particles 10-A
into unhealthy tissue 140 of liver 110 using a needle 160. Needle 160 is in fluid communication with a syringe 170, which contains a coinposition including particles 10-A suspended in a carrier fluid 180. An end 190 of needle 160 is inserted into unhealtlly tissue 140, and particles 10-A and carrier fluid 180 are then injected from syringe 170 into unhealthy tissue 140.
In certain embodiments, particles 10-A may not be suspended in a carrier fluid.
For example, particles 10-A alone can be contained within syringe 170, and injected from syringe 170 into unllealthy tissue 140.
The pressure and/or temperature within syringe 170 can be selected to limit the extent of premature bursting by particles 10-A (e.g., before particles 10-A
have reached unhealthy tissue 140). In some embodiments, the pressure within syringe 170 can be at least about 1.1 atmospheres (e.g., from about 1.1 atmospheres to about 1.5 atmospheres).
The pressure within syringe 170 can be selected, for example, to be substantially equal to the internal pressure of particles 10-A. In certain embodiinents, the temperature within syringe 170 can be at most about 32 C (e.g., at most about 20 C).
While embodiments have been described in which a needle is used to deliver particles 10-A into unhealthy tissue 140, in some embodiments, other delivery devices can be used to deliver particles 10-A into unhealthy tissue 140. As an example, particles 10-A can be delivered into uiffiealthy tissue 140 directly from a syringe. As another example, particles 10-A can be delivered into unhealthy tissue 140 using a catheter.
Alternatively or additionally, particles 10-A can be delivered into unhealtlly tissue 140 by using other kinds of techniques. For example, an incision can be made in the subject to gain access to unhealthy tissue 140, and particles 10-A can be deposited directly into unhealthy tissue 140 through the incision.
Wliile particles 10-A generally are intact when first delivered into unhealthy tissue 140 (as shown in FIG 2B), as particles 10-A are heated to body temperature (about 37 C), particles 10-Aburst, forming burst particles 10-B. As shown in FIG 2C, when particles 10-A burst, they release ferromagnetic particles 16 into unhealthy tissue 140. In certain embodiments in which coating 12 and matrix 18 are formed of a bioerodible or bioabsorbable material (described above), coating 12 and matrix 18 can be eroded and/or absorbed by the body, leaving ferromagnetic particles 16 distributed throughout unhealthy tissue 140 (as shown in FIG 2D).
FIG 2E illustrates a method of treating unhealthy tissue 140 with RF energy using an RF electrode 185. As shown, RF electrode 185 is positioned within unhealthy tissue 140 (e.g., by insertion through skin 120 of the subject). Once RF electrode 185 is positioned within unh.ealthy tissue 140, tines 195 of RF electrode 185 are deployed within unhealthy tissue 140, and RF electrode 185 is activated so that RF energy is emitted from tines 195. The RF energy emitted from tines 195 can heat unhealtlzy tissue 140 around tines 195 to treat (e.g., ablate, damage, destroy) portions of unhealthy tissue 140 that are exposed to the energy.
Various algorithms can be used when exposing the particles to RF energy. In some embodiments, the RF power source is initially set at a power level of 30 Watts, and the power is increased by 10 Watts every minute. In certain embodiments, the RF power source is initially set at a power level of 60 Watts, and the power is increased by 10 Watts every 30 seconds. The end of the procedure can be detennined, for example, by the temperature of the ablated tissue and/or by the measured impedance of the RF
power circuit. Without wishing to be bound by theory, it is believed that the presence of ferromagnetic particles 16 in unhealthy tissue 140 may eifllance the burning of unhealthy tissue 140 (which results in damage or destruction of the tissue) by RF
electrode 185.
While certain einbodunents of particles have been described, other embodiments of particles can be used to deliver material (e.g., ferromagnetic material, therapeutic agents) to a target site.

As an example, FIG. 3 shows a particle 200 that includes pores 202 and a matrix (e.g., a polymer matrix) 204. Ferromagnetic particles 206 are disposed within matrix 204 and some of pores 202. Pores 202 also include one or more gases. Like particle (FIG. lA), particle 200 has an internal pressure of at least about 1.1 atinospheres at a temperature of less than about 25 C. When particle 200 is heated to a sufficient temperature, particle 200 bursts, releasing ferromagnetic particles 206.
As shown in FIG. 3, particle 200 can be considered to include a center region, C, from the center c' of particle 200 to a radius of about r/3, a body region, B, from about r/3 to about 2 r/3, and a surface region, S, from about 2 r/3 to r. The regions can be characterized by the relative size of pores 202 present in particle 200 in each region, the density of pores 202 (the number of pores 202 per unit volume of particle 200) in each region, and/or the mass density (the density of matrix 204 and ferromagnetic particles 206 per unit volume of particle 200) in eacll region.
In general, the mean size of pores 202 in region C of particle 200 is greater than the mean size of pores 202 at region S of particle 200. In some embodiments, the mean size of pores 202 in region C of particle 200 is greater than the mean size of pores 202 in region B particle 200, and/or the mean size of pores 202 in region B of particle 200 is greater than the mean size of pores 202 at region S particle 200. The size of pores 202 in particle 200 can be measured by viewing a cross-section of particle 200. For irregularly shaped (nonspherical) pores, the maxiinum visible cross-section is used.
Generally, the density of pores 202 in region C of particle 200 is greater than the density of pores 202 at region S of particle 200. In some einbodiments, the density of pores 202 in region C of particle 200 is greater than the density of pores 202 in region B
of particle 200, and/or the density of pores 202 in region B of particle 200 is greater than the density of pores 202 at region S of particle 200.
In general, the mass density in region C of particle 200 is less than the mass density at region S of particle 200. In some einbodiments, the mass density in region C of particle 200 is less than the mass density in region B of particle 200, and/or the mass density in region B of particle 200 is less than the mass density at region S
of particle 200. Porous particles are described, for exainple, in U.S. Patent Application Publication No. US 2003/0185896 Al, published on October 2, 2003, and in U.S. Patent Application Publication No. US 2004/0096662 Al, published on May 20, 2004, both of which are incorporated herein by reference.
As another example, in certain embodiments, a particle can include a material that generates a gas, thereby causing the internal pressure of the particle to increase, during the use of the particle. Such a material is referred to herein as a gas generator. In some embodiments, the gas generator can generate gas when the particle (and, therefore, the gas generator) is heated. For example, FIG. 4A shows a particle 300 that has a coating (e.g., a polymer coating) 302 and an interior region 304 including ice pieces 306 and ferromagnetic particles 308. As particle 300 is heated (e.g., when particle 300 is delivered to a target site within a subject), ice pieces 306 melt, producing water.
Eventually, if particle 300 is heated to at least about 100 C, the water can produce water vapor, which can cause the intenlal pressure of particle 300 to increase, until particle 300 bursts, thereby releasing ferroinagnetic particles 308.
While ice has been described, in some embodiments, a particle can alternatively or additionally include one or more other types of gas generators that can cause the internal pressure of the particle to increase with an increase in temperature.
As an example, a particle can include dry ice or saline. In certain embodiments, a particle can be formed to include water. For example, FIG. 4B shows a particle 400 that includes pores 402 and a matrix (e.g., a polymer matrix) 404. Ferromagnetic particles 408 are dispersed in pores 402 and in matrix 404. Some of pores 402 also contain water. When particle 400 is exposed to a temperature of at least about 100 C, water 406 can produce water vapor that causes the internal pressure of particle 400 to increase.
Eventually, particle 400 can burst, thereby releasing ferromagnetic particles 408.
While particles that include ferromagnetic materials have been described, in some embodiments, a particle can alternatively or additionally include one or more other types of materials.
In certain embodiments, a particle can include one or more thermally and/or electrically conductive materials. In such embodiments, the particle may be used to enhance an ablation procedure. Examples of therinally conductive materials include metals (e.g., iron, aluminum, cobalt, copper, silver, molybdenum, zinc, gold, iridium) and metal alloys (e.g., steel). In some elnbodiments, a particle can include a non-metal thermally conductive material, such as silicon or carbon. Examples of electrically conductive materials include metals (e.g., silver, copper, gold, aluminum, iridiuin, zinc, iron, nickel, molybdenum, cobalt) and metal alloys (e.g., steel). Examples of materials that are both thermally conductive and electrically conductive include silver, copper, gold, aluminum, iridium, molybdenuin, zinc, and steel.
In some embodiments, a particle can include one or more therapeutic agents (e.g., drugs). The therapeutic agent can, for example, be encapsulated within the particle so that when the particle bursts, it releases the therapeutic agent (e.g., to a target site).
Alternatively or additionally, in an einbodiment of a particle including a coating, the coating can include one or more tlierapeutic agents. In some embodiments, a particle can have a coating that includes a high concentration of one or more therapeutic agents. One or more of the therapeutic agents can also be loaded into the interior region of the particle. Thus, the surface of the particle can release an initial dosage of therapeutic agent after which the body of the particle can provide a burst release of therapeutic agent.
The therapeutic agent on the surface of the particle can be the same as or different from the therapeutic agent in the body of the particle. The therapeutic agent on the surface can be applied by exposing the particle to a high concentration solution of the therapeutic agent. The therapeutic agent coated particle can include another coating over the surface the therapeutic agent (e.g., a degradable and/or bioabsorbable polymer which erodes when the particle is administered). The coating can assist in controlling the rate at which therapeutic agent is released from the particle. For example, the coating can be in the forin of a porous membrane. The coating can delay an initial burst of tllerapeutic agent release. The coating can be applied by dipping or spraying the particle. The coating can include therapeutic agent or can be substantially free of therapeutic agent.
The therapeutic agent in the coating can be the saine as or different from an agent on a surface layer of the particle and/or within the particle. A polyiner coating (e.g. an erodible coating) can be applied to the particle surface in embodiments in which a high concentration of therapeutic agent has not been applied to the particle surface. Coatings are described, for exainple, in U.S. Patent Application Publication No. US

Al, published on Apri122, 2004, which is incorporated herein by reference.

Therapeutic agents include genetic'therapeutic agents, non-genetic therapeutic agents, and cells, and can be negatively charged, positively charged, amphoteric, or neutral. Therapeutic agents can be, for exainple, materials that are biologically active to treat physiological conditions; pharmaceutically active compounds; gene therapies;
nucleic acids with and without carrier vectors; oligonucleotides; gene/vector systems;
DNA chimeras; compacting agents (e.g., DNA compacting agents); viruses;
polymers;
hyaluronic acid; proteins (e.g., enzymes such as ribozymes); immunologic species;
nonsteroidal anti-inflammatory medications; oral contraceptives; progestins;
gonadotrophin-releasing honnone agonists; cheinotherapeutic agents; and radioactive species (e.g., radioisotopes, radioactive molecules). Non-limiting exainples of tlzerapeutic agents include anti-tlirombogenic agents; antioxidants;
angiogenic and anti-angiogenic agents and factors; anti-proliferative agents (e.g., agents capable of blocking smooth muscle cell proliferation); calcium entry bloclcers; and survival genes which protect against cell death.
Exemplary non-genetic therapeutic agents include: anti-thrombotic agents such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone); anti-inflammatory agents such as dexainethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine and mesalamine;
antineoplastic/ antiproliferative/anti-mitotic agents such as paclitaxel, 5-fluorouracil, cisplatin, doxorubicin, vinblastine, vincristine, epothilones, endostatin, angiostatin, angiopeptin, monoclonal antibodies capable of bloclcing smooth muscle cell proliferation, and thymidine kinase inliibitors; anesthetic agents such as lidocaine, bupivacaine and ropivacaine; anti-coagulants such as D-Phe-Pro-Arg chloromethyl ketone, an RGD
peptide-containing compound, heparin, hirudin, antitlv-ombin compounds, platelet receptor antagonists, anti-tlirombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides;
vascular cell growth promoters such as growth factors, transcriptional activators, and translational promoters; vascular cell growth inhibitors such as growtll factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growtll factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; protein lcinase and tyrosine kinase inhibitors (e.g., tyrphostins, genistein, quinoxalines); prostacyclin analogs;
cholesterol-lowering agents; angiopoietins; antimicrobial agents such as triclosan, cephalosporins, aminoglycosides and nitrofurantoin; cytotoxic agents, cytostatic agents and cell proliferation affectors; vasodilating agents; and agents that interfere with endogenous vasoactive mechanisms.
Exemplary genetic therapeutic agents include: anti-sense DNA and RNA; DNA
coding for anti-sense RNA, tRNA or rRNA to replace defective or deficient endogenous molecules, angiogenic factors including growth factors such as acidic and basic fibroblast growth factors, vascular endotlielial growth factor, epidermal growth factor, transforming growth factor a and (3, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor a, hepatocyte growth factor, and insulin like growth factor, cell cycle inhibitors including CD inhibitors, thymidine lcinase ("TK") and otller agents useful for interfering with cell proliferation, and the family of bone morphogenic proteins ("BMP's"), including BMP2, BMP3, BMP4, BMP5, BMP6 (Vgrl), BMP7 (OP1), BMP8, BMP9, BMP10, BM1 1, BMP12, BMP13, BMP14, BMP15, and BMP16.
Currently preferred BMP's are any of BMP2, BMP3, BMP4, BMP5, BMP6 and BMP7.
These dimeric proteins can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules. Alternatively or additionally, molecules capable of inducing an upstream or downstreain effect of a BMP can be provided. Such molecules include any of the "hedgehog" proteins, or the DNA's encoding thein.
Vectors of interest for delivery of genetic therapeutic agents include:
plasmids; viral vectors such as adenovirus (AV), adenoassociated virus (AAV) and lentivirus;
and non-viral vectors such as lipids, liposomes and cationic lipids.
Cells include cells of human origin (autologous or allogeneic), including stem cells, or from an animal source (xenogeneic), which can be genetically engineered if desired to deliver proteins of interest.
Several of the above and numerous additional therapeutic agents appropriate for the practice of the present invention are disclosed in U.S. Patent No.
5,733,925, assigned to NeoRx Corporation, which is incorporated herein by reference. Therapeutic agents disclosed in this patent include the following:

"Cytostatic agents" (i.e., agents that prevent or delay cell division in proliferating cells, for exainple, by inhibiting replication of DNA or by inhibiting spindle fiber formation). Representative exainples of cytostatic agents include modified toxins, methotrexate, adriamycin, radionuclides (e.g., such as disclosed in Fritzberg et al., U.S.
Patent No. 4,897,255), protein kinase inhibitors, including staurosporin, a protein kinase C inliibitor of the following formula:

MeQ

r~~t as well as diindoloalkaloids having one of the following general structures:

IK
N

ra as well as stimulators of the production or activation of TGF-beta, including Tamoxifen and derivatives of functional equivalents (e.g., plasmin, heparin, compounds capable of reducing the level or inactivating the lipoprotein Lp(a) or the glycoprotein apolipoprotein(a)) thereof, TGF-beta or functional equivalents, derivatives or analogs thereof, suramin, nitric oxide releasing compounds (e.g., nitroglycerin) or analogs or functional equivalents thereof, paclitaxel or analogs thereof (e.g., taxotere), inhibitors of specific enzymes (such as the nuclear enzyme DNA topoisomerase II and DNA
polymerase, RNA polymerase, adenyl guanyl cyclase), superoxide dismutase inhibitors, terminal deoxynucleotidyl-transferase, reverse transcriptase, antisense oligonucleotides that suppress smooth muscle cell proliferation and the like. Other examples of "cytostatic agents" include peptidic or mimetic inhibitors (i.e., antagonists, agonists, or competitive or non-competitive inhibitors) of cellular factors that may (e.g., in the presence of extracellular matrix) trigger proliferation of smooth muscle cells or pericytes: e.g., cytokines (e.g., interleulcins such as IL-1), growth factors (e.g., PDGF, TGF-alpha or -beta, tumor necrosis factor, smooth muscle- and endothelial-derived growth factors, i.e., endothelin, FGF), homing receptors (e.g., for platelets or leukocytes), and extracellular matrix receptors (e.g., integrins). Representative exainples of useful therapeutic agents in this category of cytostatic agents addressing smooth inuscle proliferation include:
subfragments of heparin, triazolopyrimidine (trapidil; a PDGF antagonist), lovastatin, and prostaglandins El or 12.
Agents that inllibit the intracellular increase in cell volume (i.e., the tissue volume occupied by a cell), such as cytoskeletal inhibitors or metabolic inhibitors.
Representative examples of cytoskeletal ii-Alibitors include colchicine, vinblastin, cytochalasins, paclitaxel and the like, wliich act on microtubule and microfilament networks within a cell. Representative examples of metabolic inhibitors include staurosporin, trichothecenes, and modified diphtheria and ricin toxins, Pseudomonas exotoxin and the like. Trichothecenes include simple trichothecenes (i.e., those that have only a central sesquiterpenoid structure) and macrocyclic trichothecenes (i.e., those that have an additional macrocyclic ring), e.g., a verrucarins or roridins, including Verrucarin A, Verrucarin B, Verrucarin J (Satratoxin C), Roridin A, Roridin C, Roridin D, Roridin E
(Satratoxin D), Roridin H.
Agents acting as an inliibitor that bloclcs cellular protein synthesis and/or secretion or organization of extracellular matrix (i.e., an "anti-matrix agent").
Representative exainples of "anti-matrix agents" include iiihibitors (i.e., agonists and antagonists and competitive and non-competitive inhibitors) of matrix synthesis, secretion and assembly, organizational cross-linking (e.g., transglutaminases cross-linlcing collagen), and matrix remodeling (e.g., following wound healing). A
representative example of a useful therapeutic agent in this category of anti-matrix agents is colchicine, an inhibitor of secretion of extracellular matrix. Another example is tamoxifen for which evidence exists regarding its capability to organize and/or stabilize as well as diminish smootli inuscle cell proliferation following angioplasty.
The organization or stabilization may stem from the blockage of vascular smooth muscle cell maturation in to a patllologically proliferating form.
Agents that are cytotoxic to cells, particularly cancer cells. Preferred agents are Roridin A, Pseudomonas exotoxin and the like or analogs or functional equivalents thereof. A plethora of such therapeutic agents, including radioisotopes and the like, have been identified and are known in the art. In addition, protocols for the identification of cytotoxic moieties are 1u1own and employed routinely in the art.
A number of the above therapeutic agents and several others have also been identified as candidates for vascular treatment regimens, for example, as agents targeting restenosis. Such agents include one or more of the following: calciuin-channel blockers, including benzothiazapines (e.g., diltiazem, clentiazein); dihydropyridines (e.g., nifedipine, amlodipine, nicardapine); phenylalkylamines (e.g., verapamil);
serotonin pathway modulators, including 5-HT antagonists (e.g., ketanserin, naftidrofuryl) and 5-HT uptake inhibitors (e.g., fluoxetine); cyclic nucleotide patliway agents, including phosphodiesterase inhibitors (e.g., cilostazole, dipyridamole), adenylate/guanylate cyclase stimulants (e.g., forskolin), and adenosine analogs; catecholamine modulators, including a-antagonists (e.g., prazosin, bunazosine), 0-antagonists (e.g., propranolol), and a/(3-antagonists (e.g., labetalol, carvedilol); endotlzelin receptor antagonists; nitric oxide donors/releasing molecules, including organic nitrates/nitrites (e.g., nitroglycerin, isosorbide dinitrate, amyl nitrite), inorganic nitroso compounds (e.g., sodium nitroprusside), sydnonimines (e.g., molsidomine, linsidomine), nonoates (e.g., diazenium diolates, NO adducts of alkanediamines), S-nitroso compounds, including low molecular weight compounds (e.g., S-nitroso derivatives of captopril, glutathione and N-acetyl penicillamine) and high molecular weight compounds (e.g., S-nitroso derivatives of proteins, peptides, oligosaccharides, polysaccharides, synthetic polymers/oligomers and natural polymers/oligomers), C-nitroso-, 0-nitroso- and N-nitroso-compounds, and L-arginine; ACE inhibitors (e.g., cilazapril, fosinopril, enalapril); ATII-receptor antagonists (e.g., saralasin, losartin); platelet adhesion inhibitors (e.g., albumin, polyethylene oxide);
platelet aggregation inhibitors, including aspirin and thienopyridine (ticlopidine, clopidogrel) and GP IIb/IIIa inhibitors (e.g., abciximab, epitifibatide, tirofiban);
coagulation pathway modulators, including heparinoids (e.g., heparin, low molecular weigllt heparin, dextran sulfate, P-cyclodextrin tetradecasulfate), thrombin inhibitors (e.g., hirudin, hirulog, PPACK (D-phe-L-propyl-L-arg-chloromethyllcetone), argatroban), FXa inhibitors (e.g., antistatin, TAP (ticlc anticoagulant peptide)), vitamin K inhibitors (e.g., warfarin), and activated protein C; cyclooxygenase pathway inhibitors (e.g., aspirin, ibuprofen, flurbiprofen, indomethacin, sulfinpyrazone); natural and synthetic corticosteroids (e.g., dexamethasone, prednisolone, methprednisolone, hydrocortisone);
lipoxygenase pathway inhibitors (e.g., nordihydroguairetic acid, caffeic acid;
leukotriene receptor antagonists; antagonists of E- and P-selectins; inhibitors of VCAM-1 and ICAM-1 interactions; prostaglandins and analogs thereof, including prostaglandins such as PGE1 and PGI2; prostacyclin analogs (e.g., ciprostene, epoprostenol, carbacyclin, iloprost, beraprost); macrophage activation preventers (e.g., bisphosphonates); HMG-CoA reductase inhibitors (e.g., lovastatin, pravastatin, fluvastatin, simvastatin, cerivastatin); fish oils and omega-3-fatty acids; free-radical scavengers/antioxidants (e.g., probucol, vitainins C and E, ebselen, trans-retinoic acid, SOD mimics); agents affecting various growth factors including FGF pathway agents (e.g., bFGF antibodies, chimeric fusion proteins), PDGF receptor antagonists (e.g., trapidil), IGF pathway agents (e.g., somatostatin analogs such as angiopeptin and ocreotide), TGF-(3 pathway agents such as polyanionic agents (heparin, fucoidin), decorin, and TGF-(3 antibodies, EGF
pathway agents (e.g., EGF antibodies, receptor antagonists, chimeric fitsion proteins), TNF-a pathway agents (e.g., thalidomide and analogs thereof), thromboxane A2 (TXA2) patllway modulators (e.g., sulotroban, vapiprost,' dazoxiben, ridogrel), protein tyrosine kinase inhibitors (e.g., tyrphostin, genistein, and quinoxaline derivatives);
MMP pathway inhibitors (e.g., marimastat, ilomastat, metastat), and cell motility ii111ibitors (e.g., cytochalasin B); antiproliferative/antineoplastic agents including antimetabolites such as purine analogs (e.g., 6-mercaptopurine), pyrimidine analogs (e.g., cytarabine and 5-fluorouracil) and methotrexate, nitrogen mustards, alkyl sulfonates, etllylenimines, antibiotics (e.g., daunorubicin, doxorubicin), nitrosoureas and cisplatin, agents affecting microtubule dynamics (e.g., vinblastine, vincristine, colchicine, paclitaxel, epothilone), caspase activators, proteasome inhibitors, angiogenesis inhibitors (e.g., endostatin, angiostatin and squalamine), and rapamycin, cerivastatin, flavopiridol and suramin;
matrix deposition/organization pathway inhibitors (e.g., halofuginone or otller quinazolinone derivatives, tranilast); endothelialization facilitators (e.g., VEGF and RGD
peptide); and blood rheology modulators (e.g., pentoxifylline).
Therapeutic agents are described, for example, in co-pending U.S. Patent Application Publication No. US 2004/00765 82 Al, published on April 22, 2004, which is incorporated herein by reference, and in Pinchulc et al., U.S. Patent No.
6,545,097, incorporated above.
In certain embodiments, in addition to or as an alternative to including one or more therapeutic agents and/or ferromagnetic'inaterials, a particle can include one or more radiopaque materials, materials that are visible by magnetic resonance imaging (MRI-visible materials), and/or ultrasound contrast agents, which are described, for exainple, in U.S. Patent Application Publication No. US 2004/0101564 Al, published on May 27, 2004, wllich is incorporated herein by reference.
Particles can be fonned by any of a number of different methods.
As an example, a particle such as particle 10-A (FIG 1A) can be made using the system 1000 shown in FIGS. 5A and 5B. System 1000 includes a flow controller 1100, a drop generator 1200, a gelling vessel 1400, a reactor vessel 1500, an optional gel dissolution chamber 1600, and a filter 1700. Drop generator 1200 includes a concentric nozzle 1300. As shown in FIG 6A, concentric nozzle 1300 inch.ides an inner nozzle 1330 with an iiuier volume 1335 and an orifice 1310. Concentric nozzle 1300 also includes an outer nozzle 1340 with an inner volume 1345 (shaded in FIG 6A) and an orifice 1320.
Drop generator 1200 can be, for exainple, the Inotech Encapsulator unit IE-50R/NS (Inotech AG, Dottikon, Switzerland), or the model NISCO Encapsulation unit VAR D (NISCO Engineering, Zurich, Switzerland). In some einbodiments, concentric nozzle 1300 can be provided as an attaclunent to drop generator 1200. An exainple of a concentric nozzle attacliment is the model IE-5250 attaclunent (available from Inotech AG).
Flow controller 1100 delivers a solution (e.g., a polymer solution) and a mixture including ferromagnetic particles 16 (e.g., a gelling precursor mixture) to a viscosity controller 1800, which heats one or both of the solution and the mixture to achieve their respective desired viscosities prior to delivery to drop generator 1200. In certain embodiments, before being transferred to drop generator 1200, one or both of the solution and the mixture can be introduced to a high pressure pumping apparatus, such as a syringe pump (e.g., model PHD4400, Harvard Apparatus, Holliston, MA).
Alternatively or additionally, drop generator 1200 can contain a pressure control device that applies a pressure (e.g., from about 0.5 Bar to about 1.6 Bar) to one or both of the solution and the mixture (a pressure head) to control the rates at which the solution and/or mixture are transferred to drop generator 1200. Generally, the pressure applied to a given solution or mixture depends on the viscosity of the solution or mixture and/or the desired flow rate of the solution or mixture.
As shown in FIG 6B, after being delivered to drop generator 1200, a stream of the gelling precursor mixture including ferromagnetic particles 16 passes througll volume 1335 and exits inner nozzle 1330 via orifice 1310. Carbon dioxide is added to stream 1350 as stream 1350 passes through volume 1335. Thus, when streain 1350 exits inner nozzle 1330, streain 1350 includes bubbles of carbon dioxide gas. A
stream 1360 of the polymer solution passes through voluine 1345 and exits outer nozzle 1340 via orifice 1320. The streams interact as they exit the orifices. At the same time, nozzle 1300 is subjected to a periodic disturbance which results in the formation of drops 1370 having an interior region 1380 including gelling precursor, ferromagnetic particles 16, and carbon dioxide gas bubbles, and a polymer coating 1390. Drops 1370 fall into gelling vessel 1400, where the drops are stabilized by gel formation dtiring which the alginate is converted from a solution form to a gel form. The gel-stabilized drops are then transferred from gelling vessel 1400 to reactor vessel 1500, where the polymer in the gel-stabilized drops is reacted, forming particles. Thereafter, the particles are filtered in filter 1700 to remove debris, and are sterilized and packaged as a coinposition including particles. In some embodiments, the particles are transferred, prior to filtration, to gel dissoltttion chamber 1600. In gel dissolution chamber 1600, the gelling precursor (which was converted to a gel) in the particles is dissolved. After the particle formation process has been completed, the particles can be filtered, sterilized, and paclcaged, as described above.
In some embodiments, the above-described process can be modified to produce particles having, for example, an internal pressure of at least about 1.1 atmospheres at a temperature of less than about 25 C. For example, tlie particles can be formed at a temperature of less than about 25 C (e.g., at most about 20 C, at most about 15 C, at most about 10 C, at most about 5 C). Alternatively or additionally, the particles can be formed in a pressurized environment (an environment having a pressure of greater than one atmosphere). For example, the particles can be formed in a chamber in which the pressure is at least about 1.1 atmospheres (e.g., at least about 1.2 atinospheres, at least about 1.5 atmospheres, at least abottt two atmospheres).
As another example, particles such as particle 300 (FIG. 4A) can be formed, for example, using the above-described drop generation process. In some embodiments, a mixture including water and ferromagnetic particles is flowed through volume 1335 of inner nozzle 1330, and a mixture including a solution (e.g., a polymer solution) is flowed through volume 1345 of outer nozzle 1340. After the particles have been formed, they can be frozen, such that the water forms ice pieces 306. In some embodiments, the particles may then be stored in a low-temperature envirorunent, in order to limit premature melting by ice pieces 306.
As an additional example, particles such as particle 200 (FIG 3) can be formed, for example, using the process described above with respect to FIGS. 5A and 5B. In some embodiments, two solutions (e.g., a polymer solution and a gelling precursor solution), either or both including ferromagnetic particles 206, can be flowed through concentric nozzle 1300 and mixed sufficiently'to form drops that include a mixture of both solutions. Gas can be added into either or both solutions prior to inixing and/or after mixing. For example, a gelling precursor solution can be aerated with carbon dioxide gas prior to mixing, so that the gelling precursor solution includes carbon dioxide bubbles.
In certain einbodiments, drop generator 1200 can be modified such tllat, instead of including concentric nozzle 1300, drop generator 1200 includes a single nozzle. A

mixture (e.g., a polymer/gelling precursor mixture such as polyvinyl alcohol/alginate) including ferromagnetic particles 206 can then be flowed through the nozzle to form drops. In some embodiments, as the mixture is flowed through the nozzle, gas can be added into the mixture, so that the mixture includes bubbles of gas.
Particles such as particle 400 (FIG 4B) can be formed, for example, by making particle 200 and soalcing particle 200 in water, so that the water can enter some or all of pores 402.
In some embodiments, gas can be added into one or more of the mixtures or solutions that are used to make particles before the particle formation process has begun.
As an example, a solution may be aerated with a gas, and then used in a particle formation process (as described above with reference to the formation of particle 200).
In certain embodiments, particles may be formed in a gaseous environment (e.g., in a chamber), such that the particles incorporate the gas during formation.
In some embodiments, the gaseous environment cain have a pressure of more than one atmosphere (e.g., at least about 1.1 atmospheres, at least about 1.2 atmospheres, at least about 1.5 atmospheres, at least about two atmospheres), and/or a temperature of less than about C (e.g., at most about 20 C, at most about 15 C, at most about 10 C, at most about 5 C).
In some embodiments, one or more coatings can be applied to particles produced 20 by any of the above-described processes, in order to help maintain the internal pressure within the particles. In certain embodiments, the particles can be formed in an environment having a low temperature and/or a high pressure, and can be coated while they still are in the environment having the low temperature and/or high pressure. In some embodiments, particles can be both fonned and coated in a gaseous environment.
25 Particles can be coated by, for example, spraying and/or dip-coating.
In certain einbodiinents, after particles have been formed, they may be stored in an environment having a low temperature (e.g., at most about 20 C) and/or a high pressure (e.g., at least about 1.1 atinospheres). These storage conditions can help maintain the internal pressure of the particles and/or prevent the particles from bursting prematurely.

Methods of malcing particles are described, for example, in U.S. Patent Application Publication No. US 2004/0096662 Al, published on May 20, 2004, and in U.S. Patent Application No. 10/858,253, filed on June 1, 2004, and entitled "Embolization", both of which are incorporated herein by reference.
While certain embodiments have been described, other embodiments are possible.
As an example, while particles that include (e.g., encapsulate) ferromagnetic particles have been described, in some embodiments, a particle can alternatively or additionally include a ferromagnetic material having a different shape or form. For example, a particle can include a ferromagnetic material in the form of a fiber, a flalce, or a powder. In some embodiments, ferromagnetic particles, fibers, flakes, and/or powders can have a dimension (e.g., a diameter) of from about two microns to about 20 microns.
As another exainple, while particles that include carbon dioxide gas have been described, in some embodiments, a particle can alternatively or additionally include one or more other gases, such as nitrogen, oxygen, or water vapor. Typically, a gas that is included in a particle can be biocompatible.
As an additional example, while particles with a gelling precursor matrix and a polymer coating have been described, particles can have other types and combinations of materials. For example, in some embodiments, a particle can have a polymer matrix and a gelling precursor coating.
As a fiirther exainple, while particles with coatings (e.g., polymer coatings) have been described, in some embodiments, a particle may not include a coating.
As another example, while particles including ferromagnetic material have been described, in some embodiments, a particle can include other types of materials that can be used to enhance an ablation procedure. For example, a particle may include (e.g., encapsulate) a sodiuin ion solution (e.g., a sodiuin chloride solution) and/or a calcium ion soh.ttion (e.g., a calcium chloride solution). When the particle bursts at a target site, the particle can release its contents to the target site, thereby enhancing ablation of the target site.
As another exainple, in some einbodiments, a capsule can be used to deliver one or more particles to a target site. For exainple, FIG. 7 shows a capsule 500 that contains particles 502. When capsule 500 is delivered to a target site (e.g., to the tissue of a subject), capsule 500 can separate, thereby releasing particles 502 into the target site.
Capsule 500 can be used, for example, to efficiently transport multiple particles 502 to a target site. In some embodiments, capsule 500 can be pressurized, and/or its contents can be maintained at a relatively low temperature, in order to limit the likelihood of premature bursting by particles 502. In some embodiments, capsule 500 can have an internal pressure of at least about 1.1 atmospheres (e.g., at least about 1.2 atmospheres, at least about 1.5 atmospheres, at least about two atmospheres), and/or a temperature of at most about 20 C (e.g., at most about 15 C, at most about 10 C, at most about 5 C). As shown in FIG 7, capsule 500 has a maximum dimension D,,,a,. In some embodiments, maximum dimension D,,,aX can be from about 3,000 microns to about 5,000 microns.
While capsule 500 is generally cylindrical in shape, in certain embodiments, a capsule can have a different shape. For example, a capsule can be spherical or spheroidal.
As a further example, in some einbodiments, particles can be used in an RF
ablation procedure that employs a coaxial electrode (e.g., a 3.5 centimeter coaxial LeVeen electrode, available from RadioTherapeutics, Mountain View, Calif.).
For example, FIG 8A shows a portion 700 of a subject including a liver 710 and skin 720. Liver 710 includes healthy tissue 730 and unhealtliy tissue 740. FIG

illustrates the delivery of a cannula 750 into unhealthy tissue 740, using a trocar 760.
After cannula 750 has been delivered into unhealthy tissue 740, trocar 760 is removed from cannula 750 and, as shown in FIG 8C, needle 775 is inserted into cannula 750.
Needle 775 is in fluid communication with a syringe 770, which contains a composition including particles 10-A suspended in a carrier fluid 780. Particles 10-A and carrier fluid 780 are injected from syringe 770, tluough needle 775 and cannula 750, and into unliealthy tissue 740. After pai-ticles 10-A and carrier fluid 780 have been delivered, needle 775 and syringe 770 are removed from cannula 750.
While particles 10-A are generally intact when first delivered into unhealthy tissue 740 (as shown in FIG 8C), as particles 10-A are heated to body temperature (about 37 C), particles 10-A burst, thereby forming burst particles 10-B, and releasing ferromagnetic particles 16 into unhealtlly tissue 740 (as shown in FIG 8D).
As FIG 8E shows, an RF electrode 790 is then inserted into caimula 750, such that its distal end 792 enters ui-dzealthy tissue 740. As shown in FIG 8F, tines 795 are thereafter deployed within unhealthy tissue 740. RF electrode 790 can subsequently be activated so that RF energy is emitted from tines 795.
As another example, in certain embodiments, an RF electrode can be used to increase the temperature of one or more particles (e.g., particles that include ferromagnetic material) at a target site (e.g., within cancerous tissue of a subject). In some embodiments, this increase in the temperature of the particles can cause the particles to burst.
As a further example, in some embodiments in which particles release ferromagnetic material (e.g., ferroinagnetic particles) at a target site (e.g., tissue of a subject), the ferroinagnetic material can be used in an agitation ablation process. In such a process, a magnetic field can be used to agitate the ferromagnetic material, such that the ferromagnetic material heats and/or physically deforms the surrounding target site, thereby ablating the surrounding target site.
As another example, in certain embodiments, a laser can be used to ablate a target site (e.g., in which particles have released fer'romagnetic material).
As an additional exainple, in some embodiments, a particle can be contacted witll an agent (e.g., an alcohol, hydrochloric acid, sodium hydroxide, sodium citrate, sodium hexa-metaphosphate) that can dissolve or erode at least a portion of the particle. The agent can be used, for exainple, to accelerate the bursting of the particle.
The agent can be applied to the particle prior to, during, and/or after delivery of the particle to a target site. For example, in some embodiments in which a particle includes a sodium alginate coating, at least a portion of the sodium alginate coating can be dissolved by contacting the coating with sodium hexa-metaphosphate.
As a fiirther exainple, in some einbodiments, a particle (either porous or non-porous) can include at least one cavity (a hollow central region in the particle). In certain embodiments in which a particle includes a cavity, the particle can furtller include pores in the material surrounding the cavity. The particles can include one or more gases in the cavity and/or pores. For example, FIG. 8 shows a particle 600 wit11 a cavity surrounded by a matrix materia1606 (e.g., a polymer) that includes pores 604.
As another exainple, in some embodiments, a particle can include a shape memory material, wllich is capable of being configured to remeinber (e.g., to change to) a predetermined configuration or shape. In certain embodiments, particles that include a shape memory material can be selectively transitioned from a first state to a second state.
For example, a heating device provided in the interior of a delivery catheter can be used to cause a particle including a shape ineinory material to transition from a first state to a second state. Shape memory materials and particles that include shape memory materials are described in, for example, U.S. Patent Application Publication No. US

Al, published on May 13, 2004, and U.S. Patent Application No. 10/791,103, filed March 2, 2004, and entitled "Einbolic Compositions", both of which are incorporated herein by reference.
As an additional example, in some embodiments, a particle can include a surface preferential material. Surface preferential materials are described, for example, in U.S.
Patent Application No. 10/791,552, filed on March 2, 2004, and entitled "Embolization", which is incorporated herein by reference.
As a further example, in certain embodiments, particles can be linlced together to form particle chains. For example, the particles can be connected to each other by linlcs that are formed of one or more of the same material(s) as the particles, or of one or more different material(s) from the particles. Particle chains and methods of malcing particle chains are described, for exainple, in U.S. Patent Application No. 10/830,195, filed on April 22, 2004, and entitled "Embolization", which is incorporated herein by reference.
As an additional example, in some embodiments one or more particles is/are substantially nonspherical. In some embodiinents, the particles can be mechanically shaped during or after the particle formation process to be nonspherical (e.g., ellipsoidal).
In certain embodiments, particles can be shaped (e.g., molded, coinpressed, punched, and/or agglomerated with other particles) at different points in the particle manufacturing process. As an example, in certain embodiments in which the particles are formed using a gelling agent, the particles can be physically deformed into a specific shape and/or size after the particles have been contacted with the gelling agent, btit before the polymer(s) in the particles have been cross-linlced. After shaping, the polymer(s) (e.g., polyvinyl alcohol) in the particles can be cross-linlced, optionally followed by substantial removal of gelling precursor (e.g., alginate). While substantially spherical particles have been described, in some einbodiments, nonspherical particles can be manufactured and forined by controlling, for example, drop formation conditions. In some einbodiments, nonspherical particles can be formed by post-processing the particles (e.g., by cutting or dicing into other shapes). Particle shaping is described, for exainple, in Baldwin et al., U.S. Published Patent Application No. US 2003/0203985 Al, which is incorporated herein by reference.
As a further example, in certain embodiments, nonspherical (e.g., irregular) particles can be fonned and exposed to a gaseous atmosphere, such that the particles may trap gas bubbles on their surface. In some embodiments, the particles may tliereafter be coated. For example, FIG. 10A shows an irregular particle 800 including a body region 803 having a surface 801. Gas bubbles 802 are trapped on surface 801 of body region 803. FIG. l OB shows a particle 806 including body region 803, gas bubbles 802, and a coating 804.
As another example, in some embodiments a solution can be added to the nozzle of a drop generator to enhance the porosity of particles produced by the drop generator.
Examples of porosity-enhancing solutions include starch, sodium chloride at a relatively high concentration (e.g., more than about 0.9 percent, from about one percent to about five percent, from about one percent to about two percent), and calcium chloride (e.g., at a concentration of at least about 50 mM). For example, calcium chloride can be added to a sodium alginate gelling precursor solution to increase the porosity of the particles produced from the solution.
As an additional example, in some embodiments, particles having different shapes, sizes, physical properties, and/or chemical properties, can be used together in a procedure (e.g., an ablation procedure). The different particles can be delivered into the body of a subject in a predetermined sequence or siinultaneously. In certain embodiments, mixtures of different particles can be delivered using a multi-lumen catheter and/or syringe. Particles with different shapes, sizes, physical properties, and/or chemical properties are described, for example, in U.S. Patent Application Publication No. US 2004/0091543 Al, published on May 13, 2004, and in U.S. Patent Application No. 10/791,103, filed March 2, 2004, aild entitled "Einbolic Coinpositions", both of which are incorporated herein by reference.
Other einbodiments are in the claims.

Claims (31)

1. A particle having an internal pressure of at least about 1.1 atmospheres at a temperature of less than about 25°C, wherein the particle has a diameter of at most about 3,000 microns.
2. The particle of claim 1, wherein the particle comprises a gas.
3. The particle of claim 1, wherein the particle has an internal pressure of at least about 1.5 atmospheres at a temperature of at least about 35°C.
4. The particle of claim 1, wherein the particle has an internal pressure of at least about 1.5 atmospheres at a temperature of at least about 90°C.
5. The particle of claim 1, wherein the internal pressure of the particle increases by at least about five percent when the particle is heated to a temperature of at least about 25°C.
6. The particle of claim 1, wherein the internal pressure of the particle increases by at least about 10 percent when the particle is heated to a temperature of at least about 35°C.
7. The particle of claim 1, wherein the internal pressure of the particle increases by at least about 20 percent when the particle is heated to a temperature of at least about 90°C.
8. The particle of claim 1, wherein the particle bursts at a temperature of at least about 35°C.
9. The particle of claim 1, wherein the particle bursts at a temperature of at least about 90°C.
10. The particle of claim 1, wherein the particle bursts at an internal pressure of at least about 1.5 atmospheres.
11. The particle of claim 1, wherein the particle comprises a thermally conductive material, an electrically conductive material, a ferromagnetic material, or a combination thereof.
12. The particle of claim 1, wherein the particle comprises a gas generator, and when the gas generator is heated to a temperature of at least about 25°C, the internal pressure of the particle increases to at least about 1.2 atmospheres.
13. The particle of claim 12, wherein the gas generator comprises dry ice.
14. The particle of claim 12, wherein the gas generator is disposed in an interior region of the particle.
15. The particle of claim 1, wherein the particle comprises a gas generator, and when the gas generator is heated to a temperature of at least about 35°C, the internal pressure of the particle increases to at least about 1.5 atmospheres.
16. The particle of claim 1, wherein the particle comprises a gas generator, and when the gas generator is heated to a temperature of at least about 90°C, the internal pressure of the particle increases to at least about 1.5 atmospheres.
17. The particle of claim 1, wherein the particle comprises a gas generator, and when the gas generator is heated to a temperature of at least about 100°C, the internal pressure of the particle increases to at least about 1.5 atmospheres.
18. The particle of claim 17, wherein the gas generator comprises water or saline.
19. The particle of claim 1, wherein the particle comprises a coating.
20. The particle of claim 19, wherein the coating has a thickness of at most 0.02 inch.
21. A composition, comprising:
a carrier fluid; and particles disposed within the carrier fluid, the particles having an arithmetic mean diameter of at most about 3,000 microns, wherein an environment surrounding the composition has a pressure of at least about 1.1 atmospheres.
22. A capsule containing at least one of the particles of claim 1, wherein the capsule has a maximum dimension of from about 3,000 microns to about 5,000 microns.
23. The capsule of claim 22, wherein the capsule has an internal pressure of at least about 1.1 atmospheres.
24. A method, comprising:
exposing a particle with an internal pressure of at least about 1.1 atmospheres at a temperature of less than about 25°C to a temperature of at least about 35°C, wherein the particle has a diameter of at most about 3,000 microns.
25. The method of claim 24, wherein exposing the particle to a temperature of least about 35°C causes the particle to burst.
26. The method of claim 24, wherein exposing the particle to a temperature of at least about 35°C causes the internal pressure of the particle to increase to at least about 1.5 atmospheres.
27. The method of claim 24, further comprising contacting the particle with an agent that is adapted to dissolve or erode at least a portion of the particle.
28. A particle having at least one cavity and comprising a matrix including at least one polymer and a plurality of pores, wherein the particle has a diameter of about 3,000 microns or less.
29. The particle of claim 28, wherein the at least one cavity is defined by the matrix including the at least one polymer.
30. The particle of claim 28, wherein the at least one polymer comprises a polymer selected from the group consisting of polyvinyl alcohols, polyacrylic acids, polymethacrylic acids, poly vinyl sulfonates, carboxymethyl celluloses, hydroxyethyl celluloses, substituted celluloses, polyacrylamides, polyethylene glycols, polyamides, polyureas, polyurethanes, polyesters, polyethers, polystyrenes, polysaccharides, polylactic acids, polyethylenes, polymethylmethacrylates, polyethylacrylate, polycaprolactones, polyglycolic acids, poly(lactic-co-glycolic) acids, and copolymers or mixtures thereof.
31. The particle of claim 28, wherein the at least one polymer comprises polyvinyl alcohol.
CA002598680A 2005-03-02 2006-02-28 Particles Abandoned CA2598680A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/070,967 2005-03-02
US11/070,967 US7858183B2 (en) 2005-03-02 2005-03-02 Particles
PCT/US2006/007100 WO2006093969A2 (en) 2005-03-02 2006-02-28 Particles with high internal pressure for tissue ablation

Publications (1)

Publication Number Publication Date
CA2598680A1 true CA2598680A1 (en) 2006-09-08

Family

ID=36762997

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002598680A Abandoned CA2598680A1 (en) 2005-03-02 2006-02-28 Particles

Country Status (4)

Country Link
US (1) US7858183B2 (en)
EP (1) EP1853314A2 (en)
CA (1) CA2598680A1 (en)
WO (1) WO2006093969A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US7963287B2 (en) 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US8007509B2 (en) 2005-10-12 2011-08-30 Boston Scientific Scimed, Inc. Coil assemblies, components and methods
US8152839B2 (en) 2005-12-19 2012-04-10 Boston Scientific Scimed, Inc. Embolic coils
US8101197B2 (en) 2005-12-19 2012-01-24 Stryker Corporation Forming coils
US7947368B2 (en) 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
WO2008014060A2 (en) * 2006-07-27 2008-01-31 Boston Scientific Limited Microparticle
US10675298B2 (en) 2006-07-27 2020-06-09 Boston Scientific Scimed Inc. Particles
US8414927B2 (en) 2006-11-03 2013-04-09 Boston Scientific Scimed, Inc. Cross-linked polymer particles
US20080107744A1 (en) * 2006-11-06 2008-05-08 Jack Fa-De Chu Injectable hollow tissue filler
WO2009086076A2 (en) * 2007-12-28 2009-07-09 Boston Scientific Scimed, Inc. Particles for injection and processes for forming the same
US20090274764A1 (en) * 2008-04-30 2009-11-05 Do Hiep Q Hollow Foam Beads for Treatment of Glioblastoma

Family Cites Families (340)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2275154A (en) * 1940-07-10 1942-03-03 United Drug Company Method for making capsules
US2609347A (en) 1948-05-27 1952-09-02 Wilson Christopher Lumley Method of making expanded polyvinyl alcohol-formaldehyde reaction product and product resulting therefrom
JPS4820019B1 (en) * 1969-06-05 1973-06-18
US3737398A (en) 1969-11-13 1973-06-05 D Yamaguchi Method of making a polyvinyl acetal sponge buff
CS179075B1 (en) 1974-11-26 1977-10-31 Stoy Vladimir Mode of manufacture of spherical particles from polymer
US4076640A (en) * 1975-02-24 1978-02-28 Xerox Corporation Preparation of spheroidized particles
US3957933A (en) * 1975-03-05 1976-05-18 General Atomic Company Apparatus for producing microspherical particles and method for operating such apparatus
JPS51135958A (en) 1975-05-20 1976-11-25 Fuji Photo Film Co Ltd Method of making fine powder polymer having pores
US4025686A (en) * 1975-06-26 1977-05-24 Owens-Corning Fiberglas Corporation Molded composite article and method for making the article
US4034759A (en) 1975-08-27 1977-07-12 Xomed, Inc. Moisture-expandable prosthesis
US4098728A (en) 1976-01-02 1978-07-04 Solomon Rosenblatt Medical surgical sponge and method of making same
US4055377A (en) 1976-08-03 1977-10-25 Minnesota Mining And Manufacturing Company Magnetically orientable retroreflectorization particles
GB1591924A (en) * 1976-10-25 1981-07-01 Berger Jenson & Nicholson Ltd Polymer aggregates
US4159719A (en) 1977-05-09 1979-07-03 Xomed, Inc. Moisture-expandable ear wick
ES478736A1 (en) 1978-03-23 1979-06-01 Hoechst Ag Polyvinyl alcohol pellets containing a plasticizer, and method for their preparation.
DE2834539A1 (en) 1978-08-07 1980-02-21 Basf Ag MACROPOROUS POLYMERS AS CARRIER MATERIAL FOR THE COVALENT BINDING OF PROTEINS
US4793980A (en) 1978-09-21 1988-12-27 Torobin Leonard B Hollow porous microspheres as substrates and containers for catalyst
US4243794A (en) * 1978-10-10 1981-01-06 Minnesota Mining And Manufacturing Company Mixture of rough and spheroidized resin particles
US4198318A (en) * 1978-11-24 1980-04-15 Conoco, Inc. Production of high strength alumina spheres by hydrogelling corresponding slurries
US4268495A (en) 1979-01-08 1981-05-19 Ethicon, Inc. Injectable embolization and occlusion solution
US4246208A (en) * 1979-03-22 1981-01-20 Xerox Corporation Dust-free plasma spheroidization
US4346712A (en) 1979-04-06 1982-08-31 Kuraray Company, Ltd. Releasable balloon catheter
HU184722B (en) 1980-02-18 1984-10-29 Laszlo Lazar Therapeutically suitable silicone rubber mixture and therapeuticaid
US4271281A (en) 1980-05-29 1981-06-02 American Hoechst Corporation Process for preparing styrenic polymer particles
DE3031737A1 (en) * 1980-08-22 1982-04-01 Bayer Ag, 5090 Leverkusen METHOD FOR PRODUCING PEARL POLYMERISATS OF UNIFORM PARTICLE SIZE
CA1166413A (en) * 1980-10-30 1984-05-01 Edward E. Timm Process and apparatus for preparing uniform size polymer beads
US4681119A (en) 1980-11-17 1987-07-21 Schering Aktiengesellschaft Method of production and use of microbubble precursors
US4442843A (en) * 1980-11-17 1984-04-17 Schering, Ag Microbubble precursors and methods for their production and use
US4657756A (en) * 1980-11-17 1987-04-14 Schering Aktiengesellschaft Microbubble precursors and apparatus for their production and use
NZ199916A (en) 1981-03-11 1985-07-12 Unilever Plc Low density polymeric block material for use as carrier for included liquids
US4622362A (en) 1981-03-30 1986-11-11 California Institute Of Technology Polyacrolein microspheres
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
CA1177811A (en) 1981-04-13 1984-11-13 Theo G. Spek Process for the preparation of silica particles; silica particles with a narrow pore diameter distribution, catalysts made therefrom and use of these catalysts
US4428869A (en) * 1981-08-20 1984-01-31 International Flavors & Fragrances Inc. Cologne consisting of microcapsule suspension
US4456693A (en) 1982-03-08 1984-06-26 W. R. Grace & Co. Hydrocracking catalyst
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4472552A (en) 1982-09-27 1984-09-18 W. R. Grace & Co. Continuous process for making solid, free-flowing water dispersible PVA-aldehyde reaction product
US4459145A (en) 1982-09-30 1984-07-10 The United States Of America As Represented By The United States Department Of Energy Fabrication of glass microspheres with conducting surfaces
JPS59131355A (en) 1983-01-17 1984-07-28 森下仁丹株式会社 Multiple soft capsule
US4515906A (en) 1983-02-28 1985-05-07 Bend Research, Inc. Anisotropic microporous supports impregnated with polymeric ion-exchange materials
DE3834705A1 (en) 1988-10-07 1990-04-12 Schering Ag ULTRASONIC CONTRASTING AGENTS FROM GAS BUBBLES AND MICROPARTICLES CONTAINING FATTY ACID
DE3313947A1 (en) 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen MICROPARTICLES AND GAS BUBBLES CONTAINING ULTRASONIC CONTRASTING AGENTS
DE3313946A1 (en) 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen MICROPARTICLES AND GAS BUBBLES CONTAINING ULTRASONIC CONTRASTING AGENTS
CA1225585A (en) * 1983-06-30 1987-08-18 Maria T. Litvinova Composition for embolization of blood vessels
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
US4573967A (en) * 1983-12-06 1986-03-04 Eli Lilly And Company Vacuum vial infusion system
US4671954A (en) 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
US4551436A (en) 1984-04-11 1985-11-05 General Electric Company Fabrication of small dense silicon carbide spheres
DE3414924A1 (en) 1984-04-19 1985-10-31 Klaus Dr.med. Dr.med.habil. 8000 München Draenert COATED ANCHORAGE PART FOR IMPLANTS
US4674480A (en) 1984-05-25 1987-06-23 Lemelson Jerome H Drug compositions and methods of applying same
FR2566384B1 (en) * 1984-06-21 1986-09-05 Saint Gobain Vitrage IMPROVEMENTS IN TECHNIQUES FOR THE PRODUCTION OF GLASS MICROSPHERES
DE3527482A1 (en) 1984-07-31 1986-02-06 Fuji Spinning Co., Ltd., Tokio/Tokyo METHOD FOR PRODUCING GRAINY POROUS CHITOSAN
GB8419708D0 (en) * 1984-08-02 1984-09-05 Shell Int Research Preparation of silica spheres
US4623706A (en) 1984-08-23 1986-11-18 The Dow Chemical Company Process for preparing uniformly sized polymer particles by suspension polymerization of vibratorily excited monomers in a gaseous or liquid stream
US4629464A (en) 1984-09-25 1986-12-16 Tdk Corporation Porous hydroxyapatite material for artificial bone substitute
JPS61101242A (en) 1984-10-22 1986-05-20 Showa Denko Kk Production of coated substance
US4789501A (en) 1984-11-19 1988-12-06 The Curators Of The University Of Missouri Glass microspheres
US4675113A (en) 1984-11-28 1987-06-23 University Patents, Inc. Affinity chromatography using dried calcium alginate-magnetite separation media in a magnetically stabilized fluidized bed
DE3568442D1 (en) 1984-12-06 1989-04-06 Kanegafuchi Chemical Ind A method of preparation of droplets
US5106903A (en) * 1984-12-17 1992-04-21 Lehigh University Preparation of large particle size monodisperse latexes
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
JPH0678460B2 (en) 1985-05-01 1994-10-05 株式会社バイオマテリアル・ユニバース Porous transparent polyvinyl alcohol gel
JPS61293911A (en) * 1985-06-24 1986-12-24 Teisan Seiyaku Kk Sustained release preparation
SE459005B (en) * 1985-07-12 1989-05-29 Aake Rikard Lindahl SET TO MANUFACTURE SPHERICAL POLYMER PARTICLES
USH915H (en) 1985-07-22 1991-05-07 Gibbs Marylu B Controlled macroporous copolymer properties by removal of impurities in the diluent
US4742086A (en) 1985-11-02 1988-05-03 Lion Corporation Process for manufacturing porous polymer
DE3543348A1 (en) 1985-12-07 1987-06-11 Bayer Ag PEARL-SHAPED CROSS-NETWORKED MIXED POLYMERS WITH EPOXY AND BASIC AMINO GROUPS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
JPS62169723A (en) * 1986-01-22 1987-07-25 Teisan Seiyaku Kk Sustained release preparation
US4671994A (en) * 1986-02-10 1987-06-09 Materials Technology Corporation Method for producing fiber reinforced hollow microspheres
GB8610024D0 (en) 1986-04-24 1986-05-29 Unilever Plc Porous structures
US4929400A (en) 1986-04-28 1990-05-29 California Institute Of Technology Production of monodisperse, polymeric microspheres
US5262176A (en) 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
JPS6317904A (en) 1986-07-09 1988-01-25 Mitsubishi Chem Ind Ltd Production of crosslinked porous polyvinyl alcohol particle
US4743507A (en) 1986-09-12 1988-05-10 Franses Elias I Nonspherical microparticles and method therefor
US5114421A (en) 1986-09-22 1992-05-19 Polak Robert B Medicament container/dispenser assembly
US4859711A (en) 1986-10-01 1989-08-22 Alcan International Limited Hollow microspheres
CA1287459C (en) 1986-10-01 1991-08-13 Mukesh Jain Process for the preparation of hollow microspheres
US5263992A (en) 1986-10-17 1993-11-23 Bio-Metric Systems, Inc. Biocompatible device with covalently bonded biocompatible agent
EP0265924B2 (en) 1986-10-29 1998-04-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Uniform polymer particles
US5292814A (en) * 1987-04-29 1994-03-08 Ernst Bayer Process for the preparation of monodispersed polymer beads
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
GB8713263D0 (en) 1987-06-05 1987-07-08 Unilever Plc Spheroidal silica
JPH0612993B2 (en) 1987-08-10 1994-02-23 株式会社クラレ Method for producing spherical microbe-immobilized moldings
US4819637A (en) * 1987-09-01 1989-04-11 Interventional Therapeutics Corporation System for artificial vessel embolization and devices for use therewith
JPH0762054B2 (en) 1987-10-13 1995-07-05 倉敷紡績株式会社 Crosslinked polymer particles
US4804366A (en) * 1987-10-29 1989-02-14 Baxter International Inc. Cartridge and adapter for introducing a beneficial agent into an intravenous delivery system
US4850978A (en) 1987-10-29 1989-07-25 Baxter International Inc. Drug delivery cartridge with protective cover
US4981625A (en) * 1988-03-14 1991-01-01 California Institute Of Technology Monodisperse, polymeric microspheres produced by irradiation of slowly thawing frozen drops
FR2634376B1 (en) * 1988-07-21 1992-04-17 Farmalyoc NOVEL SOLID AND POROUS UNIT FORM COMPRISING MICROPARTICLES AND / OR NANOPARTICLES, AS WELL AS ITS PREPARATION
AU4191989A (en) 1988-08-24 1990-03-23 Marvin J. Slepian Biodegradable polymeric endoluminal sealing
DE3829938A1 (en) 1988-09-02 1990-03-29 Hermann Hofmann ORGANO-MINERAL DUENGER AND METHOD FOR THE PRODUCTION THEREOF
US4933372A (en) 1988-09-26 1990-06-12 Supelco, Inc. Porous rigid resins and process of preparation
US5047438A (en) 1988-09-26 1991-09-10 Supelco, Inc. Porous rigid resins and process of preparation
US5681576A (en) 1988-11-16 1997-10-28 Mdv Technologies, Inc. Method and composition for post surgical adhesion reduction
DE3841401A1 (en) 1988-12-08 1990-06-13 Martin Lemperle ALLOPLASTIC IMPLANT
US5258028A (en) 1988-12-12 1993-11-02 Ersek Robert A Textured micro implants
US4946899A (en) 1988-12-16 1990-08-07 The University Of Akron Thermoplastic elastomers of isobutylene and process of preparation
GB8900376D0 (en) 1989-01-09 1989-03-08 Nycomed As Iodinated esters
US5091205A (en) * 1989-01-17 1992-02-25 Union Carbide Chemicals & Plastics Technology Corporation Hydrophilic lubricious coatings
FR2641692A1 (en) * 1989-01-17 1990-07-20 Nippon Zeon Co Plug for closing an opening for a medical application, and device for the closure plug making use thereof
US5032117A (en) 1989-01-30 1991-07-16 Motta Louis J Tandem syringe
GB8905934D0 (en) * 1989-03-15 1989-04-26 Dow Europ Sa A process for preparing adsorptive porous resin beads
US5888930A (en) * 1989-03-27 1999-03-30 Bend Research, Inc. Asymmetric microporous beads for controlled release
US5354290A (en) 1989-05-31 1994-10-11 Kimberly-Clark Corporation Porous structure of an absorbent polymer
CA2017570C (en) * 1989-05-31 2000-12-19 James R. Gross Porous structure of an absorbent polymer
US5116387A (en) 1989-06-09 1992-05-26 American Medical Systems, Inc. Preparation of injectable polymeric bodies
US5007940A (en) 1989-06-09 1991-04-16 American Medical Systems, Inc. Injectable polymeric bodies
US5158573A (en) 1989-06-09 1992-10-27 American Medical Systems, Inc. Injectable polymeric bodies
US5190760A (en) * 1989-07-08 1993-03-02 Coopers Animal Health Limited Solid pharmaceutical composition
US5698271A (en) 1989-08-22 1997-12-16 Immunivest Corporation Methods for the manufacture of magnetically responsive particles
US5253991A (en) 1989-11-20 1993-10-19 Sumitomo Cement Co., Ltd. Apparatus for producing spheroidal inorganic particulate material
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5441746A (en) 1989-12-22 1995-08-15 Molecular Bioquest, Inc. Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US6306427B1 (en) 1989-12-28 2001-10-23 Rhone-Poulenc Nutrition Animale Pellets containing active ingredients protected against degradation in the rumen of ruminants
US5435645A (en) 1989-12-29 1995-07-25 Tecres Spa Process and apparatus for the mixing and direct emplacement of a two-component bone cement
US5147937A (en) 1990-03-22 1992-09-15 Rohm And Haas Company Process for making controlled, uniform-sized particles in the 1 to 50 micrometer range
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
JPH03297475A (en) * 1990-04-16 1991-12-27 Ken Ishihara Controlling method for emission of medicine by means of resonance sound wave
US5514090A (en) 1990-04-24 1996-05-07 Science Incorporated Closed drug delivery system
US5137928A (en) 1990-04-26 1992-08-11 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
CA2016870C (en) 1990-05-15 1994-03-29 Arnie Drudik Dispenser for storing and mixing several components
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
JP2514087Y2 (en) * 1990-05-25 1996-10-16 幸三 牧田 Balloon with detachable double-sided check valve
US6291605B1 (en) 1990-06-06 2001-09-18 Clarence S. Freeman Polymerization process with spraying step
WO1991019483A1 (en) 1990-06-20 1991-12-26 Advanced Polymer Systems, Inc. Compositions and methods for the controlled release of soluble active substances
US5236410A (en) 1990-08-02 1993-08-17 Ferrotherm International, Inc. Tumor treatment method
ATE130517T1 (en) 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd INTRAVASCULAR EMBOLIZING AGENT CONTAINING A SUBSTANCE INHIBITING ANGIOGENESIS.
US5484584A (en) * 1990-10-02 1996-01-16 Board Of Regents, The University Of Texas System Therapeutic and diagnostic use of modified polymeric microcapsules
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5120349A (en) 1990-12-07 1992-06-09 Landec Labs, Inc. Microcapsule having temperature-dependent permeability profile
US5171214A (en) 1990-12-26 1992-12-15 Abbott Laboratories Drug storage and delivery system
US5171217A (en) 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US5147631A (en) 1991-04-30 1992-09-15 Du Pont Merck Pharmaceutical Company Porous inorganic ultrasound contrast agents
FR2676927B1 (en) 1991-05-29 1995-06-23 Ibf MICROSPHERES FOR USE IN THERAPEUTIC VASCULAR OCCLUSIONS AND INJECTABLE SOLUTIONS CONTAINING THEM.
EP0586524B2 (en) 1991-06-03 2000-11-02 Nycomed Imaging As Improvements in or relating to contrast agents
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US5216096A (en) 1991-09-24 1993-06-01 Japan Synthetic Rubber Co., Ltd. Process for the preparation of cross-linked polymer particles
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
KR100259989B1 (en) 1991-10-01 2000-08-01 모리다 가쓰라 Prolonged release microparticle preparation and production of the same
JP3356447B2 (en) * 1991-10-16 2002-12-16 テルモ株式会社 Vascular lesion embolic material composed of dried polymer gel
US5258042A (en) 1991-12-16 1993-11-02 Henry Ford Health System Intravascular hydrogel implant
ATE168040T1 (en) * 1991-12-20 1998-07-15 Allied Signal Inc LOW DENSITY, HIGH SPECIFIC SURFACE MATERIALS AND ARTICLES MOLDED THEREOF FOR USE IN METAL RECOVERY
US5260002A (en) 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
BR9207043A (en) 1991-12-24 1995-12-05 Du Pont Double stabilized microparticles and coating composition
GB9200391D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200388D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
DE4201461A1 (en) 1992-01-21 1993-07-22 Mueller Schulte Detlef Dr Agent for selective hyperthermia and chemotherapy of tumours - consists of ferromagnetic particles encapsulated in matrix which is not phagocyted and is able to couple with antitumour agent
US6537574B1 (en) 1992-02-11 2003-03-25 Bioform, Inc. Soft tissue augmentation material
US5480644A (en) * 1992-02-28 1996-01-02 Jsf Consultants Ltd. Use of injectable biomaterials for the repair and augmentation of the anal sphincters
IL104963A (en) 1992-03-06 1997-09-30 Nycomed Imaging As Contrast agents comprising methylene diester unit- containing biodegradable polymers
JPH05265477A (en) 1992-03-23 1993-10-15 Pioneer Electron Corp Sound field correcting device
AU3941293A (en) 1992-04-06 1993-11-08 Uroplasty, Inc. Treatment of reflux disorder by microparticles injection
DE69306844T2 (en) 1992-04-10 1997-07-10 Mitsubishi Chem Corp Process for the preparation of spherical cross-linked acrylonitrile copolymers
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
AU4198793A (en) * 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5807323A (en) * 1992-08-13 1998-09-15 Science Incorporated Mixing and delivery syringe assembly
US6592859B1 (en) 1992-08-20 2003-07-15 Ethicon, Inc. Controlled expansion sphincter augmentation media
US5512604A (en) * 1992-08-28 1996-04-30 The Dow Chemical Company Porous copolymers having a cellular polymeric structure suitable for preparing ion-exchange resins and adsorbents
DE69319438T2 (en) * 1992-09-16 1998-12-03 Nycomed Imaging As IMPROVEMENTS TO CONTRAST AGENTS
AU4926193A (en) 1992-09-21 1994-04-12 Vitaphore Corporation Embolization plugs for blood vessels
KR960001417B1 (en) 1992-09-26 1996-01-27 한국과학기술원 Method for preparing an improved porous polymer bead
DE4232755A1 (en) 1992-09-26 1994-03-31 Schering Ag Microparticle preparations made from biodegradable copolymers
GB9221329D0 (en) * 1992-10-10 1992-11-25 Delta Biotechnology Ltd Preparation of further diagnostic agents
US5382260A (en) * 1992-10-30 1995-01-17 Interventional Therapeutics Corp. Embolization device and apparatus including an introducer cartridge and method for delivering the same
US5690666A (en) 1992-11-18 1997-11-25 Target Therapeutics, Inc. Ultrasoft embolism coils and process for using them
US5349957A (en) 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
JP3256583B2 (en) 1992-12-10 2002-02-12 株式会社リコー Electrophotographic toner and method for producing the same
US5288763A (en) * 1992-12-23 1994-02-22 The Johns Hopkins University School Of Medicine Porous, polymer beads and process of their preparation
US6482436B1 (en) 1993-01-29 2002-11-19 Ferx Incorporated Magnetically responsive composition
US5328936A (en) 1993-02-01 1994-07-12 Rohm And Haas Company Polymerization process for making porous polymeric particles
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5320639A (en) 1993-03-12 1994-06-14 Meadox Medicals, Inc. Vascular plug delivery system
US5701899A (en) 1993-05-12 1997-12-30 The Board Of Regents Of The University Of Nebraska Perfluorobutane ultrasound contrast agent and methods for its manufacture and use
US5567415A (en) 1993-05-12 1996-10-22 The Board Of Regents Of The University Of Nebraska Ultrasound contrast agents and methods for their manufacture and use
US5695740A (en) 1993-05-12 1997-12-09 The Board Of Regents Of The University Of Nebraska Perfluorocarbon ultrasound contrast agent comprising microbubbles containing a filmogenic protein and a saccharide
US5344867A (en) 1993-06-14 1994-09-06 The Bfgoodrich Company Vinylidene chloride emulsion interpolymer composition
ATE502664T1 (en) 1993-07-19 2011-04-15 Angiotech Pharm Inc METHOD OF PRODUCTION OF A STENT WITH ANTI-ANGIOGENIC COMPOSITION
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5397303A (en) * 1993-08-06 1995-03-14 River Medical, Inc. Liquid delivery device having a vial attachment or adapter incorporated therein
US5398851A (en) * 1993-08-06 1995-03-21 River Medical, Inc. Liquid delivery device
JPH0763933A (en) * 1993-08-25 1995-03-10 Ricoh Co Ltd Optical integrated circuit
US5443495A (en) 1993-09-17 1995-08-22 Scimed Lifesystems Inc. Polymerization angioplasty balloon implant device
US5531716A (en) 1993-09-29 1996-07-02 Hercules Incorporated Medical devices subject to triggered disintegration
US5556391A (en) 1993-10-01 1996-09-17 Merocel Corporation Surgical sponge device
EP1258262A3 (en) * 1993-10-28 2002-12-18 Medrad, Inc. Total system for contrast delivery
CZ208995A3 (en) 1993-12-15 1996-01-17 Bracco Research Sa Injectable ultrasound medium, process of its preparation and use
CN1075959C (en) * 1994-01-21 2001-12-12 瑟泰克斯医学有限公司 Particulate material
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5569468A (en) 1994-02-17 1996-10-29 Modi; Pankaj Vaccine delivery system for immunization, using biodegradable polymer microspheres
ATE173160T1 (en) 1994-02-17 1998-11-15 Pankaj Modi DRUGS, VACCINES AND HORMONES IN POLYLACTIDE-COATED MICROPARTICLES
WO1995025480A1 (en) 1994-03-18 1995-09-28 Cook Incorporated Helical embolization coil
US5431174A (en) 1994-04-04 1995-07-11 Via Medical Corporation Method of fluid delivery and collection
EP0757553B1 (en) 1994-04-28 2000-08-02 Primed Halberstadt Medizintechnik Gmbh One-piece dispensing device for the contamination-free administration of medicaments (cytostatica)
US5534589A (en) * 1994-05-04 1996-07-09 Minnesota Mining And Manufacturing Company Repulpable plastic films
ATE203755T1 (en) 1994-05-15 2001-08-15 Apbiotech Aktiebolag METHOD FOR PRODUCING PARTICLES AND PARTICLES THAT CAN BE PRODUCED USING THIS PROCESS
JP2535785B2 (en) 1994-06-03 1996-09-18 工業技術院長 Vascular embolic agent
US5583162A (en) 1994-06-06 1996-12-10 Biopore Corporation Polymeric microbeads and method of preparation
US5639710A (en) 1994-07-06 1997-06-17 Zeneca Limited Solid microspheres for agriculturally active compounds and process for their production
ES2096521B1 (en) 1994-08-10 1997-11-16 Univ La Laguna BIODEGRADABLE SYNTHETIC POLYMER MICROSPHERES IN THE MANUFACTURE AND ELABORATION OF REACTIVE EQUIPMENT FOR THE PREPARATION OF RADIOPHARMACEUTICAL MEDICINES.
KR100341192B1 (en) 1994-08-17 2002-08-22 보스톤 사이언티픽 코포레이션 Implant, and method and device for inserting the implant
DE9414868U1 (en) 1994-09-13 1994-12-15 Klein Hans Martin Vascular embolization particles
US6099864A (en) 1994-12-02 2000-08-08 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration In situ activation of microcapsules
US5827531A (en) 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
DK175166B1 (en) * 1995-01-03 2004-06-21 Cook William Europ Method of manufacturing an assembly for placing an embolization coil in the vascular system and such assembly as well as an apparatus for advancing the assembly
DE69632392T2 (en) * 1995-01-27 2004-09-16 Scimed Life Systems, Inc., Maple Grove Embolisation
US6179817B1 (en) * 1995-02-22 2001-01-30 Boston Scientific Corporation Hybrid coating for medical devices
DE69521025T2 (en) 1995-03-07 2001-10-04 Menlo Care Inc Means to improve sphincter function with controlled expansion
US5876372A (en) * 1995-03-22 1999-03-02 Abbott Laboratories Syringe system accomodating seperate prefilled barrels for two constituents
US5569193A (en) 1995-03-22 1996-10-29 Abbott Laboratories Syringe system accommodating separately storable prefilled containers for two constituents
US5637087A (en) 1995-03-22 1997-06-10 Abbott Laboratories Prefilled, two-constituent syringe
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
ATE212545T1 (en) * 1995-03-28 2002-02-15 Fidia Advanced Biopolymers Srl NANOSPHERES WITH A BIOCOMPATIBLE POLYSACCHARIDE
US5779668A (en) 1995-03-29 1998-07-14 Abbott Laboratories Syringe barrel for lyophilization, reconstitution and administration
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US6312407B1 (en) 1995-06-05 2001-11-06 Medtronic Percusurge, Inc. Occlusion of a vessel
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
US5657756A (en) 1995-06-07 1997-08-19 Ctf Systems Inc. Method and systems for obtaining higher order gradiometer measurements with lower order gradiometers
US5766147A (en) 1995-06-07 1998-06-16 Winfield Medical Vial adaptor for a liquid delivery device
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US6096344A (en) 1995-07-28 2000-08-01 Advanced Polymer Systems, Inc. Bioerodible porous compositions
US5840387A (en) 1995-07-28 1998-11-24 Aegis Biosciences L.L.C. Sulfonated multiblock copolymer and uses therefor
US5558822A (en) 1995-08-16 1996-09-24 Gas Research Institute Method for production of spheroidized particles
US5888546A (en) * 1995-08-28 1999-03-30 The Regents Of The University Of California Embolic material for endovascular occlusion of abnormal vasculature and method for using the same
US5833361A (en) 1995-09-07 1998-11-10 Funk; James E. Apparatus for the production of small spherical granules
CA2161863A1 (en) 1995-10-31 1997-05-01 Michael Vivian Sefton Angiogenic material and uses thereof
US5752974A (en) 1995-12-18 1998-05-19 Collagen Corporation Injectable or implantable biomaterials for filling or blocking lumens and voids of the body
DK0928182T3 (en) 1996-01-11 2002-08-26 Duoject Inc Delivery system for medicines packed in pharmaceutical bottles
US5702361A (en) * 1996-01-31 1997-12-30 Micro Therapeutics, Inc. Method for embolizing blood vessels
US5895398A (en) 1996-02-02 1999-04-20 The Regents Of The University Of California Method of using a clot capture coil
AUPN978296A0 (en) 1996-05-10 1996-05-30 Gray, Bruce N Targeted hysteresis hyperthermia as a method for treating cancer
US6051247A (en) * 1996-05-30 2000-04-18 University Of Florida Research Foundation, Inc. Moldable bioactive compositions
US5855615A (en) * 1996-06-07 1999-01-05 Menlo Care, Inc. Controller expansion sphincter augmentation media
US5792478A (en) 1996-07-08 1998-08-11 Advanced Uro Science Tissue injectable composition and method of use
US5741331A (en) * 1996-07-29 1998-04-21 Corvita Corporation Biostable elastomeric polymers having quaternary carbons
US5830178A (en) 1996-10-11 1998-11-03 Micro Therapeutics, Inc. Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide
US5695480A (en) 1996-07-29 1997-12-09 Micro Therapeutics, Inc. Embolizing compositions
US5823198A (en) 1996-07-31 1998-10-20 Micro Therapeutics, Inc. Method and apparatus for intravasculer embolization
TW421658B (en) 1996-07-31 2001-02-11 Kanebo Ltd Porious spherical particles and the preparation process for preparing thereof
US5902832A (en) 1996-08-20 1999-05-11 Menlo Care, Inc. Method of synthesizing swollen hydrogel for sphincter augmentation
US5813411A (en) 1996-08-20 1998-09-29 Menlo Care, Inc. Method of deforming tissue with a swollen hydrogel
US5785642A (en) 1996-10-18 1998-07-28 Micro Therapeutics, Inc. Methods for treating urinary incontinence in mammals
US5756127A (en) 1996-10-29 1998-05-26 Wright Medical Technology, Inc. Implantable bioresorbable string of calcium sulfate beads
KR100544835B1 (en) * 1996-11-13 2006-01-24 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 Storage and delivery of pressurized gases in microbubbles
US6139963A (en) 1996-11-28 2000-10-31 Kuraray Co., Ltd. Polyvinyl alcohol hydrogel and process for producing the same
DE29724255U1 (en) 1996-12-18 2000-10-05 Alpha Bioverfahrenstechnik Gmb Microcapsules
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
JP4570696B2 (en) 1997-04-10 2010-10-27 ジョンズ・ホプキンズ・ユニバーシティ Gas syringe device
JP4102459B2 (en) 1997-05-14 2008-06-18 森下仁丹株式会社 Seamless capsule for synthesizing biopolymer and method for producing the same
US6056844A (en) 1997-06-06 2000-05-02 Triton Systems, Inc. Temperature-controlled induction heating of polymeric materials
JP2002503991A (en) * 1997-06-13 2002-02-05 マイクロ・テラピューティクス・インコーポレーテッド Syringe and luer hub having novel shape and method of forming embolus
US6048908A (en) 1997-06-27 2000-04-11 Biopore Corporation Hydrophilic polymeric material
US5959073A (en) 1997-07-07 1999-09-28 Southwest Research Institute Method for preparing polymeric beads
US6056721A (en) 1997-08-08 2000-05-02 Sunscope International, Inc. Balloon catheter and method
EP1009317A4 (en) 1997-08-28 2001-01-24 Boston Scient Corp System for implanting a cross-linked polysaccharide fiber and methods of forming and inserting the fiber
US6538026B1 (en) 1997-09-11 2003-03-25 Provasis Therapeutics, Inc. Compositions useful for remodeling body spaces
US6476069B2 (en) 1997-09-11 2002-11-05 Provasis Therapeutics Inc. Compositions for creating embolic agents and uses thereof
AU739610B2 (en) 1997-11-07 2001-10-18 Salviac Limited Implantable occluder devices for medical use
US5951160A (en) 1997-11-20 1999-09-14 Biomet, Inc. Method and apparatus for packaging, mixing and delivering bone cement
DE19752585B4 (en) 1997-11-27 2007-06-28 Inotech Ag Device and method for encapsulating microbial, plant and animal cells or of biological and chemical substances
US6019750A (en) 1997-12-04 2000-02-01 Baxter International Inc. Sliding reconstitution device with seal
RU2215542C2 (en) 1998-02-23 2003-11-10 Массачусетс Инститьют Оф Текнолоджи Biodecomposing polymers able recovery of form
DK1062278T3 (en) 1998-02-23 2006-09-25 Mnemoscience Gmbh Polymers with shape memory
US6003566A (en) 1998-02-26 1999-12-21 Becton Dickinson And Company Vial transferset and method
US6059766A (en) 1998-02-27 2000-05-09 Micro Therapeutics, Inc. Gynecologic embolotherapy methods
ATE262976T1 (en) 1998-03-07 2004-04-15 Inotech Ag METHOD AND DEVICE FOR ENCAPSULATING MICROBIAL, PLANT AND ANIMAL CELLS OR OF BIOLOGICAL AND CHEMICAL SUBSTANCES
US6047861A (en) * 1998-04-15 2000-04-11 Vir Engineering, Inc. Two component fluid dispenser
US6224794B1 (en) 1998-05-06 2001-05-01 Angiotech Pharmaceuticals, Inc. Methods for microsphere production
US6224630B1 (en) 1998-05-29 2001-05-01 Advanced Bio Surfaces, Inc. Implantable tissue repair device
CA2334223C (en) 1998-06-04 2008-11-18 New York University Endovascular thin film devices and methods for treating and preventing stroke
US6267154B1 (en) 1998-06-05 2001-07-31 Abbott Laboratories System for storing mixing and administering a drug
US6165193A (en) 1998-07-06 2000-12-26 Microvention, Inc. Vascular embolization with an expansible implant
US6264861B1 (en) 1998-08-05 2001-07-24 Xeikon Nv Method for producing rounded polymeric particles
US6315709B1 (en) 1998-08-07 2001-11-13 Stereotaxis, Inc. Magnetic vascular defect treatment system
US6152943A (en) * 1998-08-14 2000-11-28 Incept Llc Methods and apparatus for intraluminal deposition of hydrogels
CA2248592A1 (en) 1998-08-31 2000-02-29 Christopher D. Batich Microspheres for use in the treatment of cancer
US6296622B1 (en) 1998-12-21 2001-10-02 Micrus Corporation Endoluminal device delivery system using axially recovering shape memory material
EP1119625B1 (en) * 1998-10-07 2005-06-29 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
FR2784580B1 (en) * 1998-10-16 2004-06-25 Biosepra Inc POLYVINYL-ALCOHOL MICROSPHERES AND METHODS OF MAKING THE SAME
US6238335B1 (en) 1998-12-11 2001-05-29 Enteric Medical Technologies, Inc. Method for treating gastroesophageal reflux disease and apparatus for use therewith
JP2000189511A (en) 1998-12-25 2000-07-11 Kaneka Medeikkusu:Kk Embolization material
US6162377A (en) 1999-02-23 2000-12-19 Alberta Research Council Inc. Apparatus and method for the formation of uniform spherical particles
US6296604B1 (en) 1999-03-17 2001-10-02 Stereotaxis, Inc. Methods of and compositions for treating vascular defects
US6306425B1 (en) 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
US6368658B1 (en) * 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
US6280457B1 (en) 1999-06-04 2001-08-28 Scimed Life Systems, Inc. Polymer covered vaso-occlusive devices and methods of producing such devices
ATE280579T1 (en) 1999-08-27 2004-11-15 Southern Res Inst INJECTABLE BUPRENORPHINE MICROSPHERES COMPOSITIONS AND USE THEREOF FOR REDUCING HEROIN AND ALCOHOL CONSUMPTION
FR2797769B1 (en) 1999-09-01 2003-07-25 Cis Bio Int RADIOPHARMACEUTICAL PRODUCTS AND THEIR PREPARATION PROCESS
JP2001079011A (en) 1999-09-14 2001-03-27 Akira Morimoto Embolization coil and its manufacture
US6277392B1 (en) 1999-09-16 2001-08-21 Carbon Medical Technologies, Inc. Tissue injectable composition
US6238403B1 (en) 1999-10-04 2001-05-29 Microvention, Inc. Filamentous embolic device with expansible elements
US6602261B2 (en) 1999-10-04 2003-08-05 Microvention, Inc. Filamentous embolic device with expansile elements
US6586364B2 (en) * 1999-12-08 2003-07-01 Pentax Corporation Heat-sensitive microcapsule and recording medium using same
KR100335866B1 (en) * 2000-01-06 2002-05-10 박호군 Microspheric Embolic Materials Having Duel Structure of Poly(Vinyl Acetate) Core/Poly(Vinyl Alcohol) Shell, and Method for Preparing The Same
US6306419B1 (en) 2000-02-23 2001-10-23 Aegis Biosciences, Llc Medical uses of styrene sulfonate polymers
WO2001066016A1 (en) 2000-03-06 2001-09-13 Scimed Life Systems, Inc. Embolic agents visible under ultrasound
US6652883B2 (en) 2000-03-13 2003-11-25 Biocure, Inc. Tissue bulking and coating compositions
AU4566001A (en) 2000-03-13 2001-09-24 Biocure Inc Embolic compositions
WO2001084565A2 (en) * 2000-05-02 2001-11-08 Kuehnle Manfred R Method and apparatus for manufacture of magnetizable microparticles
US6423332B1 (en) 2000-05-26 2002-07-23 Ethicon, Inc. Method and composition for deforming soft tissues
DE10026620A1 (en) 2000-05-29 2002-03-07 Gerhard Quelle Biocompatible material for cell and tissue implantation, useful e.g. for drug release or cosmetic tissue augmentation, consisting of spherical particles having (semi-)permeable or porous outer shell and internal cavity
US6355275B1 (en) * 2000-06-23 2002-03-12 Carbon Medical Technologies, Inc. Embolization using carbon coated microparticles
JP2002017848A (en) 2000-07-12 2002-01-22 Terumo Corp Intravitally injectable particulate and method for preparing the same
US6394965B1 (en) 2000-08-15 2002-05-28 Carbon Medical Technologies, Inc. Tissue marking using biocompatible microparticles
ATE449596T1 (en) 2000-08-15 2009-12-15 Univ Illinois METHOD FOR PRODUCING MICROPARTICLES
AU2001294772A1 (en) 2000-09-27 2002-04-08 Microtek Laboratories, Inc. Macrocapsules containing microencapsulated phase change materials
AUPR098200A0 (en) 2000-10-25 2000-11-16 Sirtex Medical Limited Production of low density radionuclide containing microspheres
AUPR098300A0 (en) * 2000-10-25 2000-11-16 Sirtex Medical Limited Polymer based radionuclide containing microspheres
US6545097B2 (en) * 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
JP2005513081A (en) 2000-12-13 2005-05-12 パーデュー・リサーチ・ファウンデイション Microencapsulation of drugs by solvent exchange
US6632531B2 (en) 2001-02-15 2003-10-14 Rohm And Haas Company Porous particles, their aqueous dispersions, and method of preparation
US6887857B2 (en) 2001-04-27 2005-05-03 Scimed Life Systems, Inc. Microparticle protection of therapeutic agents
US20030032935A1 (en) * 2001-08-10 2003-02-13 Scimed Life Systems, Inc. Packages facilitating convenient mixing and delivery of liquids
US7918883B2 (en) 2002-02-25 2011-04-05 Boston Scientific Scimed, Inc. Non-invasive heating of implanted vascular treatment device
US7094369B2 (en) 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7131997B2 (en) 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US7218962B2 (en) 2002-03-29 2007-05-15 Boston Scientific Scimed, Inc. Magnetically enhanced injection catheter
US7053134B2 (en) 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US7838699B2 (en) 2002-05-08 2010-11-23 Biosphere Medical Embolization using degradable crosslinked hydrogels
US7449236B2 (en) 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US20040076582A1 (en) * 2002-08-30 2004-04-22 Dimatteo Kristian Agent delivery particle
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US7588825B2 (en) 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
US7792568B2 (en) 2003-03-17 2010-09-07 Boston Scientific Scimed, Inc. MRI-visible medical devices
US7906148B2 (en) * 2003-07-31 2011-03-15 Boston Scientific Scimed, Inc. Latex medical articles for release of antimicrobial agents
US20050037047A1 (en) * 2003-08-11 2005-02-17 Young-Ho Song Medical devices comprising spray dried microparticles
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US7901770B2 (en) 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
US7736671B2 (en) 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US20050238870A1 (en) 2004-04-22 2005-10-27 Marcia Buiser Embolization
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization

Also Published As

Publication number Publication date
US20060199009A1 (en) 2006-09-07
WO2006093969A2 (en) 2006-09-08
WO2006093969A3 (en) 2008-04-24
US7858183B2 (en) 2010-12-28
EP1853314A2 (en) 2007-11-14

Similar Documents

Publication Publication Date Title
US7858183B2 (en) Particles
US7976823B2 (en) Ferromagnetic particles and methods
US9463426B2 (en) Methods and systems for coating particles
US7727555B2 (en) Particles
WO2005034912A2 (en) Ferromagnetic particles and methods
US9750695B2 (en) Cross-linked polymer particles
US20090053318A1 (en) Forming Embolic Particles
US9283035B2 (en) Tissue-treatment methods
US8101197B2 (en) Forming coils
EP1963386B1 (en) Block copolymer particles
US9481752B2 (en) Polymeric particles comprising vinyl formal, vinyl alcohol and vinyl acetate monomer units
US20100198210A1 (en) Particles
US20090068279A1 (en) Microspheres with surface projections
US20080045654A1 (en) Polymer particles including covalently bonded chemical species
US10675298B2 (en) Particles
US20080145658A1 (en) Freeze Thaw Methods For Making Polymer Particles
US20080008647A1 (en) Biodegradable polymer particles

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130228